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The United States has seen rising rates of opioid abuse, which have led to 
changing policies designed to curb opioid prescribing. These guidelines and policies 
generally exclude hospice and palliative care from prescribing restrictions. However, no 
studies to date have thoroughly examined the impact of these policies to identify if there 
are unintended consequences affecting opioid prescribing within hospice and palliative 
care.  
 This is the first known qualitative description study to explore the perceptions of 
hospice and palliative care clinicians on how the opioid epidemic and related policies are 
affecting opioid prescribing within the specialty. The study addressed the literature gap 
by answering the following two research questions: 1. How has the opioid epidemic and 
related policies affected opioid prescribing practices among hospice and palliative care 
clinicians, and 2. How do hospice and palliative care clinicians perceive patients’ end of 
life care has been impacted by the opioid epidemic and related policies? 
 The research was guided by the Theory of Planned Behavior and used in vivo 
coding and content analysis to describe the phenomenon using the participants’ own 
language. Findings from the study revealed that the opioid epidemic and related policies 
have had four categories of impact on the patient, clinician, nursing, and specialty. A total 
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We must appreciate that severe constant pain will destroy the morale of the 
sturdiest individual. . . . But . . . we are often loathe to give liberal amounts of 
narcotics because the drug addiction itself may become a hideous spectacle. (Dr. 
Warren Cole, Pioneering Cancer Surgeon, Circa 1956) 
 
Statement of the Problem 
Substance use and addiction have long plagued Americans. However, recent 
decades have seen a rise in rates of opioid use and unintentional overdose deaths that 
reframe the context of a modern substance use disorder. In a 2018 report, the U.S. 
Surgeon General and the Secretaries of the U.S. Department of Health and Human 
Services and the Substance Abuse and Mental Health Services Administration suggested 
that the rates of opioid use have reached epidemic proportions (U.S. Department of 
Health and Human Services, 2018). The scope of this epidemic has resulted in enactment 
of policies at the state and federal level to curb the problem. These policies have resulted 
in a reduction in the numbers of opioids being prescribed (Jones, Bruera, Abdi, & 
Kantarjian, 2018). It is clear that the medical community is in the midst of transition, as 
society at large determines how to most appropriately manage pain in light of the 
addiction potential of opioid medications. However, opioids remain a mainstay for 
treatment of pain for patients nearing end of life (Gabbard et al., 2018). Potential 
unintended consequences of policy changes could have a detrimental impact on hospice 
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and palliative care patients by limiting access to opioids and increasing the prevalence of 
untreated symptoms or distress. If present, these unintended consequences could 
ultimately result in increased suffering at the end of life. Currently, no identified 
literature exists that descriptively characterizes opioid prescribing practices among  
hospice and palliative care clinicians and how these practices might have changed due to 
the opioid epidemic or state and federal policies.  
Purpose of the Study 
The purpose of this study was to descriptively examine opioid prescribing 
practices among hospice and palliative care clinicians as these practices relate to the 
opioid epidemic and associated policies.  
Research Questions 
 This study asked the following research questions:  
1. How has the opioid epidemic and related policies affected opioid prescribing 
practices among hospice and palliative care clinicians? 
2. How do hospice and palliative care clinicians perceive patients’ end of life care 
has been impacted by the opioid epidemic and related policies? 
Significance of the Study 
No current literature appears to exist that qualitatively describes the opioid 
prescribing practices among hospice and palliative care clinicians related to the opioid 
epidemic and associated policies. Given the prevalence of opioid prescribing in hospice 
and palliative care and the need for these medications to palliate the symptoms of patients 
nearing end of life, the lack of existing evidence exploring clinicians’ perceptions of 
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opioids is a gap that warrants study. Should this study reveal that the opioid epidemic or 
policies have impacted opioid prescribing in the setting of hospice and palliative care, it 
may reflect that patients are being undermedicated or suffering as a result of unintended 
consequences related to policy or cultural changes intended to deter opioid misuse and 
overdose deaths.  
Significance of the Opioid Misuse Problem 
Despite representing nearly 5% of the world’s population, Americans use nearly 
80% of the world’s supply of prescription opioids (Rummans, Burton, & Dawson, 2018). 
The increase in use of prescription opioids is associated with an increase in addiction 
(Kolodny et al., 2015). It is estimated that 25% of Americans who are prescribed opioids 
for non-cancer pain struggle with addiction (Centers for Disease Control and Prevention, 
2017e). The increase in use of prescription opioids has also been correlated with an 
increase in use of illicit opioids, overdoses, and unintentional deaths (Centers for Disease 
Control and Prevention, 2017d). Nationally, drug overdoses now represent the number 
one cause for accidental mortality, even surpassing motor vehicle accidents (Centers for 
Disease Control and Prevention, 2017a). The soaring rate of overdose deaths may be a 
causative factor for a declining national life expectancy, particularly among white 
Americans (Gomes, Tadrous, Mamdani, Paterson, & Juurlink, 2018). 
Such a prolific and frequent misuse of opioids is associated with unintentional 
overdoses, whose prevalence has continued to increase over time. Specifically, from 2000 
to 2010, unintentional overdoses from opioids increased 400% in the United States 
(McHugh, Nielsen, & Weiss, 2015). Unfortunately, many of these overdoses result in 
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death. Since 1999, more than 183,000 Americans have died from opioid related 
overdoses (Centers for Disease Control and Prevention, 2017d). Between the period of 
2010 to 2015 the national death rate from drug overdoses increased from 12.3 to 16.3 per 
100,000 (Rudd, 2016). The prevalence of overdose deaths increased again in 2016 to 19.8 
per 100,000. In 2017, the last year data is available, the age-adjusted rate of opioid 
overdose deaths in the United States increased to 21.7 per 100,000 individuals (Centers 
for Disease Control and Prevention, 2017b). However, some research suggests that rates 
of overdose deaths related to opioids may be 20 percent higher than currently reported 
(Ruhm, 2017). National and regional surveys of substance abuse rely on self-reporting. 
Failure to capture true prevalence is likely to be related to inaccuracies with self-
reporting due to the sensitivity of the topic.   
States with the highest rates of overdose deaths are located in the Appalachian 
and surrounding regions including Western North Carolina. West Virginia has the highest 
rate nationally with 57.8 per 100,000 individuals dying from drug overdose (Centers for 
Disease Control and Prevention, 2017d). Approximately 26 states, including North 
Carolina saw significant increases in rates of opioid-related overdose deaths in 2017 
compared to 2016 and subsequent years (Centers for Disease Control and Prevention, 
2017b). The demographics of the opioid epidemic are comparable to trends associated 
with overdose. Nationally, in 2017, 67.5 percent (28,498) of overdose victims were male 
and 79 percent (33,450) were white, non-Hispanic. Individuals aged 25-54 are 
disproportionally affected by this epidemic and collectively account for 45 percent of all 
opioid related overdose deaths (The Henry J. Kaiser Family Foundation, 2017).   
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Data from the 2016 National Survey on Drug Use and Health suggest that over 
28.6 million Americans aged 12 or older are active users of illicit drugs (or used an illicit 
drug within the past thirty days). This accounts for all illicit substances (e.g. stimulants, 
sedatives, opioids, methamphetamines, hallucinogens, etc). Although, a majority of these 
individuals reported marijuana use as the primary illicit drug, in some states it is now 
legal. Surveys now show that a majority of opioid misuse in the United States occur with 
prescription opioids (e.g. oxycodone, hydrocodone, morphine, etc). Prevalence of opioid 
misuse has continued to climb with each annual survey. In 2014, it was reported that 1.9 
million Americans had an opioid use disorder primarily related to prescription 
medications. In 2014, an additional 586,000 individuals reported an opioid use disorder 
involving heroin (Substance Abuse and Mental Health Services Administration, 2017b). 
In the 2016 National Survey on Drug Use and Health, approximately 11.5 million 
Americans over the age of 12 reported misuse of prescription opioids. In 2016, an 
additional 948,000 individuals used heroin (Ahrnsbrak, 2016). A majority of respondents 
(62.3%) reported that they were taking opioids to treat pain. Approximately 12.9 percent 
of respondents reported misuse of opioids to feel good or get high. Other commonly 
reported reasons included relaxation (10.8%), helping with emotions (3.9%), helping with 
insomnia (3.3%), and experimentation (3%) (Ahrnsbrak, 2016). 
Historical Background of the Opioid Problem 
An understanding of the problem of opioid use in America is rooted in a complex 
historical context. National data show that the upward trend of opioid overdose deaths 
began in the 1990s and have spiked significantly in recent years (The Henry J. Kaiser 
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Family Foundation, 2017).  The etiology of this trend is likely multifactorial. The 1990s 
were a decade marked by a national movement in the medical and nursing communities 
to better identify and treat pain in the clinical setting (Baker, 2017). Pain control was seen 
as generally lacking and in need for standardization. Guidelines were created identifying 
effective pain control as a patient right and pain management became a significant 
measure for quality improvement. As such, many accrediting organizations and 
healthcare systems (e.g. U.S. Department of Veterans Affairs and Joint Commission) 
adopted protocols naming pain as a fifth vital sign (Baker, 2017). This policy served to 
ensure that bedside providers were asking about pain control and offering treatment when 
appropriate. Clinicians were taught that there were no objective indicators for pain and to 
rely solely on the subjective report of the patient. Subsequently, patients’ perceptions of 
their pain and adequacy of treatment became questions used to assess the clinical 
experience in post-hospitalization surveys (Baker, 2017). Through these systemic 
changes, the pendulum for control of pain management swung heavily to favor patients 
and resulted in more liberal use of opioids in clinical settings (Kolodny et al., 2015).  
The 1990s were also a decade heralded by heavy marketing on the behalf of the 
pharmaceutical industry to promote opioid prescribing (Kolodny et al., 2015). In 1996, 
Purdue Pharma released OxyContin, a long-acting variation of oxycodone (Netherland & 
Hansen, 2017). OxyContin would eventually become the leading opioid prescribed in 
America and would gross Purdue Pharma $31 billion over the next decade (Van Zee, 
2009). Nationally, oxycodone prescriptions increased nearly 500% between the years 
2000 and 2015 (Kolodny et al., 2015). To achieve this success, Purdue Pharma initiated 
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an effective marketing campaign to convince prescribers that OxyContin was non-
addicting (Kolodny et al., 2015). It was later discovered that leadership of the family 
owned pharmaceutical company were aware of the addicting nature of their opioid 
product. As a result, in 2007, the company and three top executives plead guilty to federal 
charges of misleading the public and were fined $634.5 million (Kolodny et al., 2015; 
Maxwell, 2011). However, OxyContin would continue to be extremely profitable and a 
commonly used method for management of chronic pain (Jonas, Young, Oser, Leukefeld, 
& Havens, 2012).  
A shifting culture within the medical community to embrace opioid prescribing 
occurred despite a lack of sound scientific evidence to support the practice (Baker, 2017). 
Early evidence for chronic opioid prescribing was based primarily on two studies in the 
early 1980s, which found little incidence of addiction when opioids were used for the 
treatment of acute pain in burn units (Perry & Heidrich, 1982; Porter & Jick, 1980). 
However, these studies were cross-sectional and failed to assess for addiction with 
chronic use of opioids. A 1980 letter to the editor of the New England Journal of 
Medicine by Dr. Porter, a New York pain specialist was also frequently cited as evidence 
that opioids posed little risk of addiction (Leung, Macdonald, Stanbrook, Dhalla, & 
Juurlink, 2017).  
These early studies allayed concerns from physicians and contributed in a shift 
toward experts recommending opioid prescribing for chronic pain (Baker, 2017). 
Increasingly, it has become clear that utilization of opioids to treat chronic, non-cancer 
pain is not substantiated by clinical research (Centers for Disease Control and Prevention, 
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2017c). To the contrary, it is now widely understood that opioids, when used chronically 
can be harmful and should be avoided (Jamison, Sheehan, Scanlan, Matthews, & Ross, 
2014). In 2016, the Centers for Disease Control and Prevention (CDC) released new 
clinical guidelines that recommend minimizing dosing and limiting the duration of 
opioids to less than seven days of use (Centers for Disease Control and Prevention, 
2017c). Additionally, many states including North Carolina are enacting policies 
designed to limit the availability of prescribed opioids (North Carolina Medical Board, 
2017). 
Many of the recent policies enacted at the federal and state level within the past 
few years (e.g. Comprehensive Addiction Recovery Act, SUPPORT Act, and NC STOP 
Acts) have had little time for evaluation of their effectiveness at curbing opioid abuse and 
prescribing. Although rates of addiction and overdose continue to climb, it appears that 
nationally, opioid prescribing reached its peak in 2012, when 81.2 opioids were 
prescribed per 100 people. As of 2017, this number had fallen dramatically, nearly 28 
percent to 58.5 opioids prescribed per 100 people (Centers for Disease Control and 
Prevention, 2017e). The reason for this decline is likely complex and multifactorial. 
However, new policies and guidelines, and increased regulatory scrutiny are almost 
certainly influential in affecting provider willingness to prescribe opioids.  
History of Federal Drug Policy and Response to the Opioid Epidemic 
The current opioid epidemic is not the first within the borders of the United 
States. However, it is believed to be the worst, with more individuals affected by 
addiction and death than during any previous historical era. The etiology of the opioid 
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epidemic is complex and multifactorial and heavily influenced by public policy. Most 
researchers believe that the nature of current opioid addiction is largely iatrogenic due to 
increasing rates of opioid prescribing among physicians (Madras, 2017; Wright et al., 
2014).  
Iatrogenic causes of opioid addiction are not a new phenomenon. The late 1800s 
and early 1900s were a time when many physicians prescribed opioids (e.g. laudanum) to 
white women leading characteristically to frequent addiction within this demographic. A 
series of public policies were enacted such as the Pure Food and Drug Act of 1906, 
Smoking Opium Exclusion Act of 1909, and the Harrison Narcotic Act of 1914, which 
drastically reshaped the prescribing of opioids (Courtwright, 2009). The Harrison 
Narcotic Act initiated taxation and registration for any physician or pharmacist that 
respectively prescribed or dispensed narcotic drugs. Subsequently, these policies resulted 
in a drastic reduction in the supply of prescription opioids and led to a shift in use of 
illicit opioids for those with addiction (Courtwright, 2009). 
The 1920s and 1930s were associated with the passing of more legislation to curb 
the growing illicit drug trade. In 1924, the Heroin Act was passed which prohibited 
heroin in all forms. The Narcotic Drug Import and Export Act was passed in 1922, which 
effectively regulated the drug trade (The National Alliance of Advocates for 
Buprenorphine Treatment, 2016). 1932 saw the passage of the Uniform State Narcotic 
Act, designed to create a uniform policy of drug regulation across the nation. In 1938, the 
Food, Drug, and Cosmetic Act was passed granting regulatory authority for the safety 
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and approval of drugs to the Food and Drug Administration, which was created in 1927 
(The National Alliance of Advocates for Buprenorphine Treatment, 2016).  
The 1950s and 1960s also heralded further drug reform policies. In 1951, the 
Boggs Act imposed strict criteria for prison sentencing for those convicted of drug 
crimes. The Narcotic Control Act of 1956 further increased the penalties established 
under the Boggs Act (The National Alliance of Advocates for Buprenorphine Treatment, 
2016). In 1965, the Food, Drug and Cosmetic Act was amended to include other types of 
illicit drugs such as hallucinogens and stimulants (Quinn & McLaughlin, 1973).  
The 1960s, 1970s, and 1980s were decades associated with significant change in 
federal drug policy driven by politicization (i.e. the war on drugs) and a culture 
embracing the criminalization of drug activity. The Controlled Substances Act was 
passed in 1970, which consolidated previous drug laws by categorizing all controlled 
substances into five schedules (The National Alliance of Advocates for Buprenorphine 
Treatment, 2016). The Drug Enforcement Agency was established in 1973 to be the 
primary agency tasked with enforcement of federal drug laws. The Narcotic Addict 
Treatment Act of 1974 allowed registration of methadone clinics for the treatment of 
opioid addiction. The Anti-Drug Abuse Act of 1986 increased the federal response to 
foreign drug trafficking, increased sentencing for drug offenders (particularly associated 
with crack cocaine), and improved funding for addiction treatment. The Office of 
National Drug Control Policy was legislatively created through the Anti-Drug Abuse Act 
of 1988, which also stipulated funding for the treatment of injection drug users who were 
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at high risk of contracting acquired immune deficiency syndrome (AIDS) (The National 
Alliance of Advocates for Buprenorphine Treatment, 2016). 
The 2000s and 2010s were marked by a federal response to the growing opioid 
epidemic through policies designed to increase access to addiction treatment. The Drug 
Addiction Treatment Act (DATA) of 2000 allowed for physician registration to prescribe 
medication assisted treatment (MAT) in the community. DATA was later revised both 
through passage of new legislation and federal regulation to further expand access by 
increasing patient limits under the program (The National Alliance of Advocates for 
Buprenorphine Treatment, 2016).  
Recent Policies Related to the Opioid Epidemic 
The past several years have seen comprehensive policies enacted at the state and 
federal level to combat the opioid epidemic. The Comprehensive Addiction Recovery Act 
of 2016 is a federal law that incorporated many other pieces of legislation to expand 
access to treatment, prevention, and research for substance abuse (Whitehouse, 2016). 
Funding was provided through state grants designed to incentivize the development and 
proliferation of PDMPs and other tools to reduce opioid prescribing and diversion. Use of 
PDMP databases were further stipulated through passage of the federal Substance Use 
Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and 
Communities (SUPPORT) Act, which was signed into law in November 2018 (Walden, 
2018). This law mandates that prior to prescribing an opioid, a clinician must review a 
state PDMP database. Similar language is found in the North Carolina Strengthen Opioid 
Misuse and Prevention (STOP) Act, signed into law in 2017 (North Carolina General 
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Assembly, n.d.). The STOP Act also incorporates many of the recommendations found in 
the CDC guidelines for limited dosing and duration of opioids for acute and chronic pain. 
Both the federal SUPPORT Act and the North Carolina STOP Act have language that 
specifically excludes palliative care and hospice clinicians from many of the stipulations 
of the law that would likely be a direct burden to providing care. However, there is 
growing concern among some experts that increased utilization of PDMP databases, even 
if not mandatory, might reduce access to opioids even for patients that meet clinical 
indication (Finley et al., 2017).  
Guidelines and Position Statements Related to the Opioid Epidemic 
In 2016, the CDC released comprehensive guidelines regarding the treatment of 
acute and chronic pain. These guidelines discouraged opioid prescribing for chronic pain 
and recommended limiting morphine equivalent doses to less than 90mg per day, 
avoiding long-acting opioids, and tapering opioids as tolerable. The guidelines also 
encouraged prescribing naloxone (an opioid antagonist), urine drug screening, and 
frequent review of a prescription drug monitoring program (PDMP) prior to prescribing. 
Concurrent prescribing of an opioid with a benzodiazepine was also discouraged. It is 
noteworthy that these guidelines excluded hospice and palliative care, as it is clear that 
patients in these settings would have an undue burden given the need of these 
medications to ensure that symptoms are well managed (Centers for Disease Control and 
Prevention, 2017c).  
Although these guidelines were voluntary and specifically excluded hospice and 
palliative care, some believe that the weight of the recommendations would still limit 
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access to opioids in this population. The American Medical Association released a 
position statement voicing concerns of unintentional consequences of the guidelines, as 
insurers and policy makers could potentially act to limit reimbursement and access to 
comprehensive pain management (American Medical Association, n.d.). Additionally, the 
American Cancer Society also released a position statement suggesting that the 
guidelines fail to address the cancer survivor, who might have chronic pain following 
treatment and continue to need access to opioids to palliate their symptoms (American 
Cancer Society, 2016).  
The CDC guideline suggests tapering of opioids, which has possibly led to some 
clinicians rapidly tapering or discontinuing opioids in some patients (Darnall et al., 
2018). A number of pain experts collectively signed an open letter to clinicians decrying 
the increasing practice of forcing patients with chronic pain to rapidly taper their opioids, 
which can potentially lead to functional debilitation, withdrawal symptoms, and possible 
illicit drug use. Consequences might even include suicide as reported in the Veterans 
Health System (Darnall et al., 2018). The leaders go as far as calling the trend a 
“humanitarian crisis,” which implies an ethical violation of the fundamental tenets of 
medicine and nursing of primum non nocere. Although, the article does not explicitly 
refer to patients or clinicians involved with hospice or palliative care, it is nevertheless an 
important article that addresses the conflicting aspect of the current medical response to 
the opioid crisis. Both palliative care and hospice providers are often at the forefront of 
managing pain, both in the inpatient and outpatient settings. It is often in collaboration 
with other medical providers that might feel it is prudent in the current prescribing 
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climate to rapidly titrate or discontinue a patient’s opioids. This may worsen symptoms 
and diminish quality of life.  
In 2018, the American Society for Pain Management and the Hospice and 
Palliative Nurses Association released a joint statement reaffirming the need for nurses to 
advocate for pain management and ensure appropriate treatment including opioids for 
those patients nearing end of life. In so doing, nurses fulfill their ethical duty to the 
patient. Both organizations appear concerned that there are many barriers that may 
potentially limit access to appropriate symptom management including changes to health 
care systems. Although not explicitly stated, changes made to health systems through 
policy or new guidelines risk unintentional barriers, limiting access to treatment (Coyne, 
Mulvenon, & Paice, 2018). 
Factors Influencing Opioid Policy 
Political factors. Historically in the United States, many drug policies were 
enacted to target drug offenses in minority populations. Examples of such policies 
include the opium smoking laws of the late 1800s focused mostly on Chinese immigrants, 
marijuana laws in the Southwest in the early 1900s biased towards Mexican immigrants, 
and cocaine laws in the 1920s targeting African Americans (Drug Policy Alliance, n.d.). 
Similarly, in 1971, President Nixon declared a war on drugs that politically targeted the 
liberal anti-war establishment protesting the Vietnam conflict and African Americans 
who had been recently successful in protesting social change through the civil rights 
movement. By creating federal policies that criminalized substances that were associated 
with these groups (e.g. marijuana in the case of liberal protestors and heroin in the case of 
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poor inner-city African Americans), the president used the powers of the office to shift 
the social narrative and discredit their respective social movements. John Ehrlichman, a 
top aide in the Nixon White House would later state that the president could not directly 
criminalize the social movement but through drug policies they could target and arrest the 
movement leaders thereby villainizing these groups in the eyes of the public (Drug Policy 
Alliance, n.d.).   
Some perceive the war on drugs as being further escalated by the presidential 
election of President Reagan in 1981. Reagan effectively capitalized on social fears and 
developed a platform of a law and order specifically focused on drug crimes, particularly 
among minority groups. Nancy Reagan also influenced the national discourse 
surrounding drug use through development of the abstinence program of “Just Say No” 
(Drug Policy Alliance, n.d.). This national discourse resulted in a public hysteria 
surrounding drugs and crime. National polls revealed that over 68% of individuals in 
1989 cited drugs as the number one national problem. This figure had grown dramatically 
from 1985, when only 2% of Americans cited drugs as being a top priority (Drug Policy 
Alliance, n.d.). 
Federal drug policy during the Reagan era explicitly targeted drugs more 
frequently used by African Americans such as “crack” cocaine. The purported “crack 
epidemic” was primarily isolated within inner-city black communities due in part to the 
inexpensive nature of this cocaine derivative. Cocaine in powder form was more 




The war on drugs has had a profound impact on the African American population. 
Although African Americans are no more likely than white Americans to use drugs, 
African Americans are incarcerated for drug crimes at a rate six to ten times that of their 
white counterparts (Netherland & Hansen, 2017). Strict federal and state sentencing laws 
have disproportionally affected minority populations by often mandating minimum 
sentences for simple possession of an illegal drug. Soaring rates of minority incarceration 
mean that among middle aged African American men, more are likely to have been 
incarcerated than to have joined the military or graduated college (Netherland & Hansen, 
2017). Both federal and state drug polices through the war on drugs have also often 
displaced the most vulnerable by disqualifying those with drug convictions from low 
income housing or jobs. This displacement of the vulnerable increased rates of 
homelessness, poverty, and crime (Matto & Cleaveland, 2016).   
Social factors. The current opioid epidemic is a socially complex phenomenon 
that has many influencing factors. While the specific etiology is often tied to the 
increased prescribing of opioids among medical clinicians, the nature of addiction is 
rooted in a much broader phenomenological paradigm. Addiction is often referred to as a 
“disease of despair,” a term first coined by Princeton sociologists who noted that 
increased mortality among white, low-middle income, middle aged individuals was 
associated with overdoses, alcohol-related cirrhosis, and suicides (Case & Deaton, 2017). 
The nature of increased mortality in this demographic appears to reflect a trend of mental 
health disparity. However, the underlying nature of depression and despair is clearly 
rooted in a deeper sociological context.  
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Societal trends of addiction and overdoses are evident in a larger cultural context 
of helplessness, often in geographic areas that are associated with high rates of 
unemployment and economic distress (Case & Deaton, 2017). These trends are 
particularly evident in rural areas such as Appalachia (Meit, Heffernan, & Tanenbaum, 
2017). In fact, Appalachia serves as a social epicenter of the opioid overdose epidemic. In 
2015, opioid overdose deaths occurred in rural Appalachia at a rate 65 percent higher 
than the rest of the nation (Meit et al., 2017). Rural Appalachia is also an area that has 
historically been associated with higher rates of unemployment and poverty, particularly 
following the decline in industry, which long served as a primary driver for economic 
opportunity (Jonas et al., 2012). The loss of the coal industry and de-unionization of the 
jobs that are left have had a profound impact on the social structure of these rural 
communities. Coal jobs, which were often a guaranteed path to middle-class, served as a 
form of social capital in these communities. The loss of jobs, status, and income shifted 
culture and social capital to alternative forms. The sale, trade, and use of opioids and 
other illicit substances formed a new type of social capital that provided status and social 
hierarchy for members of affected communities (Jonas et al., 2012). 
The illicit sale of opioids fueled an underground economy in communities that 
had few other economic opportunities (Quinones, 2016). A culture of opioid misuse and 
medication divergence has exacerbated the addiction phenomenon. Although the rate of 
opioid prescriptions is clearly related to addiction prevalence, many individuals misuse 
these medications without actually being prescribed opioids (Kuehn, 2014). A majority of 
those addicted to opioids first gained access to medications through family or friends 
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(Keyes, Cerdá, Brady, Havens, & Galea, 2014). Given the ample supply of opioids in a 
community via iatrogenic prescribing, there were many opportunities for those inclined to 
abuse these medications. 
 Technological factors. In the 1990s and early 2000s, at the start of the epidemic, 
opioid prescribing often occurred without the benefits of technology. Prescriptions were 
hand written, allowing for possible modification and forgery by a patient. Notations of 
prescriptions were made within a paper chart, making it difficult to reference historical 
information or dosing trends. Electronic medical records (EMR), now widely adopted, 
were less frequently used in that era by community physicians, many of whom were 
prescribing opioids. In 2011, national rates of adoption for EMR in primary care just 
reached 68 percent (Xierali et al., 2013). Electronic medical records allow a clinician to 
see the full clinical picture including how frequently medications are prescribed, adverse 
effects, and drug interactions. Utilization of an EMR also encourages sharing of 
information between clinics, which might discourage doctor-shopping or the deviant 
behavior of an addicted patient. Use of electronic prescribing through an EMR facilitates 
transfer of an opioid without a patient physically having the prescription. Such techniques 
facilitate patient care while mitigating risky behaviors. Research also suggests that an 
EMR provides an effective method of reducing opioid abuse by lowering the default pill 
counts associated with prescriptions (Chiu et al., 2018). The infrequent use of EMRs and 
the inherent lack of these benefits likely contributed to rising rates of opioid prescribing 
and abuse.  
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Prescription drug monitoring programs (PDMP) are a technology to discourage 
opioid abuse. Similar to lack of EMRs, early opioid prescribing lacked an ability to 
consistently coordinate the information to various prescribers and pharmacies. Patients 
could easily present to multiple emergency departments or physician offices complaining 
of pain, each giving a prescription for an opioid. This practice known as “doctor 
shopping” existed in an information vacuum. Many states have now implemented 
PDMPs as a database system to facilitate communication between prescribers and 
pharmacists and therefore discourage unnecessary opioid prescriptions. A prescriber is 
able to access the PDMP database and see that a patient has recently obtained an opioid 
from a different prescriber and can make the decision whether another prescription is 
clinically necessary. Pharmacists can also access the database and can contact the 
prescriber with concerns (Finley et al., 2017).  
Technology in how opioids are manufactured has also had a role in both 
facilitating and preventing abuse. When OxyContin was introduced to the market in 
1996, the drug was easy to crush, which facilitated abuse potential. Crushing of the long 
acting OxyContin altered the pharmacokinetics improving bioavailability through 
snorting or intravenous use. These unintended routes of administration facilitated the 
drugs euphoric effects and likely were a factor in increasing the desirability of the 
medications with addicted individuals (Lofwall, Moody, Fang, Nuzzo, & Walsh, 2012). 
The Food and Drug Administration has encouraged drug manufactures to incorporate 
tamper-resistance technology into medications that are at risk of abuse (Center for Drug 
Evaluation and Research, 2018). OxyContin was reformulated to include this technology 
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in 2013, which makes it more difficult to crush or change the intended route of 
administration. Tamper deterrence technology has been found to discourage abuse 
(Michna, Kirson, Shei, Birnbaum, & Ben-Joseph, 2014).  
 Legal and ethical factors. Increasingly, federal and state policies have been 
implemented to curb the rates of opioid prescribing in an attempt to reduce the prevalence 
of addiction, drug overdoses, and related deaths. Policies such as implementation of a 
prescription drug monitoring program (PDMP) have been associated with reduction in 
the rates of opioids prescribed by the medical community. For example, in 1999, when a 
PMDP was enacted in Kentucky there was a significant decrease in the numbers of 
opioids prescribed, leading to a reduction in the supply of these medications in affected 
communities (Substance Abuse and Mental Health Services Administration, 2017a). 
Other states have had similar rates of reduction when PDMP database were implemented 
(Finley et al., 2017).  
Policies implemented to reduce the supply of prescription opioids have generally 
had some success in states most impacted by the epidemic (Haegerich, Paulozzi, Manns, 
& Jones, 2014). However, rates of addiction have remained widespread even as 
prescription opioids have become increasingly difficult to access. With fewer prescription 
opioids on the illicit market there has been a transition to other types of opioids including 
heroin (McHugh et al., 2015). Supply of cheap, black-tar heroin has flooded the market 
from Mexico and has met the existing demand in areas hardest hit by addiction. 
Unfortunately, heroin is often mixed with other substances including fentanyl and have 
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further exacerbated overdoses as the potency of the opioids are difficult to gauge 
(Quinones, 2016). 
Drug laws and policy are grounded in the ethical principles and societal norms of 
the time. Many drug laws restrict one’s natural autonomy to engage in behaviors that the 
society deems dangerous or culturally unacceptable. The ethical principal of beneficence 
is also evident in modern drug laws associated with access to naloxone, a reversal agent 
important for drug overdoses. Finally, the ethical principal of justice is increasingly 
discussed within society due to the history of drug policies disproportionately impacting 
minorities. The ethics of beneficence and justice are important ethical factors influential 
in ensuring that patients at end-of-life maintain adequate access to opioids if needed to 
ensure a pain free death.  
 Economic factors. The economics of access, availability and price of opioids and 
other illicit substances can significantly affect rates of addiction. Many policies are 
implemented with the goal of shifting the economics of addiction by reducing supply and 
raising prices, thus discouraging use (Rose, 2017). Research reveals that consumption of 
opioids is generally price-elastic, meaning that as price of a drug increases due to reduced 
supply, there is a proportional reduction in the demand of that product (Olmstead, Alessi, 
Kline, Pacula, & Petry, 2015). Economists and psychologists have determined that this 
elasticity supports a theory that addiction behavior still favors rational decision making. 
Rational addiction theory suggests that the past utilization of an addictive substance such 
as opioids, will inform the decisions of the addicted individual as they seek future supply 
(Caulkins & Nicosia, 2010). As a supply of opioids becomes scarce or expensive, 
22 
 
economic influences lead an individual to switch methods or substances to continue their 
addictive behaviors. An example of this phenomenon is the shift to heroin use in the 
United States, likely due to reduction and price fluctuations in the domestic supply of 
prescription opioids in illicit markets (Rose, 2017).   
Poverty is a known risk factor for addiction (Matto & Cleaveland, 2016). The 
social stressors of poverty worsen one’s ability to cope with or seek treatment for 
addiction. Subsequently, those in poverty are more likely to relapse than those with more 
affluent socioeconomic status. Poverty often limits options for addiction treatment by 
barring access to for-profit treatment centers or mental health providers that require 
medical insurance (Matto & Cleaveland, 2016). Like addiction, poverty is a risk factor 
for the cycle of despair and hopelessness characterized by concurrent mental illness and 
depression. Both poverty and addiction increase risk of police contact, incarceration, 
joblessness, and homelessness. These factors have a cyclical relationship whereby 
poverty exacerbates addiction and addiction exacerbates poverty (Matto & Cleaveland, 
2016).  
Data regarding the impact of opioid addiction on employment is conflicting. 
Some studies have suggested that over 50% of unemployed men report taking opioids, 
which could possibly reflect a correlation with opioid use and occupational injury. 
However, other studies have found that up to 85% of drug addiction treatment in the 
United States is covered under private health insurance, which likely implies current 
employment (Currie & Schnell, 2018). Regardless, data clearly show that opioid 
addiction can have a role in driving the economic output of those affected. The 
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Organization on Economic Cooperation and Development (OECD) recently reported that 
the opioid epidemic is likely partly responsible for declines in employment participation 
within the United States (Organization for Economic Cooperation and Development, 
2018).  
Use of Opioids in Hospice and Palliative Care 
Opioids have long been used in hospice and palliative care to palliate symptoms. 
In this setting, opioids are primarily used for treatment of pain and dyspnea associated 
with advanced illness or the dying process (Blinderman & Billings, 2015). Opioid use 
among hospice patients is widely prevalent and medications are administered with the 
ethically justified goal of ensuring a “good death” (van den Beuken-van Everdingen et 
al., 2007). A recent study found that nearly 80 percent of respondents define a “good 
death” as being pain free (Meier et al., 2016). Historical data from the National Hospice 
Outcomes Project revealed that nearly 90 percent of patients were prescribed an opioid 
and 55 percent of these patients had a dose change at some point during their hospice care 
(Portenoy et al., 2006). However, despite the prevalence of opioid use among hospice 
patients, it is estimated that more than 75% of hospices under-treat or fail to properly 
manage pain (Herr et al., 2010). Older adults, such as those frequently seen by palliative 
care clinicians also frequently fail to receive appropriate pain management. These 
patients often have chronic comorbidities, polypharmacy, cognitive deficits, functional 
limitations, and medication sensitivity, which may lead to complications and concern 
among prescribers (Herr et al., 2010). For these reasons, pain among both hospice and 
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palliative care patients may also be difficult to appropriately assess and therefore might 
limit treatment.  
There are data to support the efficacy of opioids used for managing pain in 
patients that are nearing end of life (Blinderman & Billings, 2015). However, more 
research is needed. When dosed appropriately, opioids used in the treatment of cancer 
pain can be given without significant side effects such as somnolence or anorexia (P. 
Wiffen, Derry, & Moore, 2014). Previous studies on the use of opioids for palliating 
dyspnea are few but do show clinical utility when administered orally or parenterally 
(Barnes, McDonald, Smallwood, & Manser, 2016). However, studies reveal that 
clinicians underutilize opioids in the palliative treatment of dyspnea, often due to fears of 
adverse effects (Verberkt et al., 2017). 
Definition of Terms 
Palliative care is often defined as a medical specialty focused on relieving 
suffering and maximizing quality of life for those with chronic or life-threatening 
conditions (National Institute on Aging, 2017). The World Health Organization and other 
national and international associations regard palliative care as involving the assessment 
and treatment of pain and other distressing symptoms (World Health Organization, n.d.a). 
Although it is generally agreed upon that palliative care focuses on symptom relief, the 
operationalization of this may differ significantly based on organizational structure and 
priorities. For the purposes of this study, palliative care was operationally self-defined by 
the clinicians’ job description.  
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The definition of hospice is more concise and well defined than that of palliative 
care. Hospice refers to end of life care and includes a similar focus on comfort and 
symptom relief. Hospice care is operationally defined as being appropriate for those 
patients who are felt to have a life expectancy of six months or less (National Institute on 
Aging, 2017).  
Pain is often defined as the subjective experience of discomfort related to tissue 
damage (Kumar & Elavarasi, 2016). Pain is recognized to be a complex phenomenon 
with multidimensional etiology rooted in physiological, emotional, psychosocial, and 
spiritual processes. Pain can be classified into acute or chronic by duration of symptoms. 
Pain is also commonly characterized by type (e.g. visceral, neuropathic, non-cancer vs 
cancer) (Kumar & Elavarasi, 2016). 
Opioids are defined as a class of medications either chemically or synthetically 
derived from the opium poppy plant. For the purposes of this study, opioids refer to 
prescription medications regulated by the Controlled Substances Act. Examples of these 
medications include morphine, hydrocodone, oxycodone, fentanyl, methadone, codeine, 
and derivatives of these medications.  
Clinicians are defined as a licensed physician or nurse practitioner working in the 
specialty of hospice and/or palliative care. All types of licensure and training such as 
osteopathy vs allopathy or adult-gerontology vs family, were included as long as the 
clinician currently practiced within the specialty of hospice and palliative care. Other 
clinician types such as nurses, social workers, pharmacists, and chaplains, although often 
26 
 
instrumental in forming a clinical plan that includes opioids, were excluded from this 
study as they are not licensed prescribers.   
Methodology 
 A qualitative descriptive methodology was used to conduct this study. Interviews 
of hospice and palliative care clinicians were conducted to examine the research question. 
Qualitative description offers a method that is well suited for characterizing the 
phenomenon of interest. The methodological focus is on naturalistic inquiry, which 
allowed study within the hospice and palliative care environment in attempt to describe 
and characterize opioid prescribing (Kim, Sefcik, & Bradway, 2017; Sandelowski, 2000). 
Qualitative description is a method that allows thorough description of the phenomenon 
by those experiencing it (i.e. hospice and palliative care clinicians) and should help 
address gaps in the literature (Willis, Sullivan-Bolyai, Knafl, & Cohen, 2016). The 
method is particularly well suited for identification of a problem (Neergaard, Olesen, 
Andersen, & Sondergaard, 2009). The method is also appropriate for research that has 
limited time and resources (Bradshaw, Atkinson, & Doody, 2017). In the setting of 
limited previous research, qualitative description can serve as a structure to identify 
clinicians’ perceptions of the opioid epidemic and barriers and facilitators to prescribing 
opioids. Although not explicitly identified, several studies examining topics surrounding 
opioid prescribing have utilized what appear to be qualitative description as a method 
(Click, Basden, Bohannon, Anderson, & Tudiver, 2018; Fleming, Bapat, & Varisco, 





 The study was guided by the Theory of Planned Behavior (TPB). The TPB exists 
as a model for understanding behavior that is not fully under one’s control. As such, the 
theory and the relationship of its constructs are useful in predicting most human behavior 
(Ajzen, 1991). In the case of conceptually understanding the impact of the opioid 
epidemic on hospice and palliative care, this theory has high utility given the hypothesis 
that the theoretical constructs of social norms, perceived control, and attitudes affect 
clinical decision making as providers decide whether to prescribe opioids. The theory has 
been used multiple times in the past as a conceptual framework to explain prescribing 
behaviors (Ali Murshid & Mohaidin, 2017).  For the purposes of this study, the TPB was 
used to develop the interview guide.  
 
Figure 1.1 The Theory of Planned Behavior (Azjen, 1991) 
 
 
The TPB specifies that the antecedents to intention will influence a behavior, 
making it more or less likely to occur (Ajzen, 1985, 1991; Montano & Kasprzyk, 2015). 
Factors that increase or decrease the positive or negative perception of attitudes, 
subjective norms, or control will be reflected in the behavior. In the case of opioid 
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prescribing in hospice and palliative care, attitudes reflect the internalized value that one 
places on the act. Previous research has shown that clinicians may feel concern regarding 
the prescribing of opioids (Childers & Arnold, 2012; Gardiner et al., 2012). The TPB 
suggests that these concerns of risk for addiction, adverse effects, or policies would 
reflect negative attitudes regarding opioid prescribing and would likely lessen the 
intention to perform the behavior. Pharmaceutical marketing may be a factor that also 
influences clinician attitudes toward prescribing (Ali Murshid & Mohaidin, 2017). 
Pharmaceutical marketing has been shown to be effective at shaping attitudes and 
affecting prescribing patterns, making prescribing more likely (Ali Murshid & Mohaidin, 
2017). Pharmaceutical marketing is believed to have been an instrumental factor in 
promoting opioid prescribing and facilitating the opioid crisis (Kolodny et al., 2015; Van 
Zee, 2009).  
Subjective norms, which are influenced through the formation of normative 
beliefs might also stem from the social dialogue and discourse one hears about an 
important topic. In the case of the opioid epidemic, national discourse heard on news, 
radio, or in social conversations could possibly influence the normative beliefs of an 
individual (Gardiner et al., 2012). If a hospice clinician works in a medical environment 
in which they hear colleagues speak negatively about opioid prescribing, the individual 
might perceive the behavior as being unsupported by their social group. To date, it 
appears that much of the current research suggests negative attitudes and subjective 
norms exist in outside medical specialties like primary care and the emergency 
department (Franklin, Fulton-Kehoe, Turner, Sullivan, & Wickizer, 2013; Harle et al., 
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2015; Hooten & Bruce, 2011; Jamison et al., 2014; Kennedy-Hendricks, Busch, et al., 
2016; Sinnenberg et al., 2017). However, it seems possible that given the necessary 
interaction among clinicians from different medical specialties, that attitudes and 
subjective norms could be influential even outside of a clinician’s own peer group. 
Similarly, subjective norms might also be influenced by interaction the clinician has with 
their patients. Patient requests for opioids might increase the likelihood of prescribing 
(Oyler, Deep, & Chang, 2018). Interaction with a pharmacist might also contribute to the 
clinician’s normative beliefs about the safety and efficacy of an opioids (Ali Murshid & 
Mohaidin, 2017). The TPB suggests that these social norms are influential on whether the 
behavior (i.e. opioid prescribing) is realized (Ajzen, 1985, 1991; Montano & Kasprzyk, 
2015). 
Perceived control, as influenced by control beliefs and perceived power, also 
influences the intentionality of a behavior (Ajzen, 1985, 1991; Montano & Kasprzyk, 
2015). In the case of opioid prescribing, a clinician would be influenced be their 
perception of control over their clinical decision making. Control beliefs would also be 
influenced by factors that are perceived to make the behavior more difficult (Ali Murshid 
& Mohaidin, 2017). Policies and guidelines, if interpreted to be restrictive of opioid 
prescribing, might lessen the perceived control and subsequent behavior. Factors such as 
use of a PDMP, which is statutorily required in some states, has been shown to be 
perceived by some clinicians as a hassle or time-consuming to use  (Click et al., 2018; 
Cushman et al., 2017). It seems likely that a clinician that feels restricted by the use of a 
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PDMP or similar policy would be less likely to demonstrate the behavior of opioid 
prescribing.  
The construct of perceived control implies incomplete volition over the process of 
the behavior. Although clinicians wield substantial judgement in deciding the clinical 
plan, ultimately the scope of practice is determined regulatorily by outside agencies, 
including state and federal organizations. Clinicians who are fearful of regulatory 
oversight such as were identified in previous studies, might feel reduced control over 
their prescribing, which the TPB suggests would be influential in decreasing the behavior 
(Click et al., 2018; Cushman et al., 2017; Franklin et al., 2013).  
Assumptions 
The researcher for this study assumed that hospice and palliative care clinicians 
would be honestly willing to discuss their opioid prescribing patterns. It was also 
assumed that clinicians currently practicing in these settings would have an 
understanding of the opioid epidemic, even if they were not familiar with related policies. 
Additionally, given the theoretical framework, it was assumed that prescribers were 
influenced by a variety of external factors that are outside one’s control. 
Delimitations 
 This study is limited to: 
1. Physicians and nurse practitioners currently practicing within hospice and 
palliative care settings in North Carolina. The limitation to a single state helped 
control for variation in state policies.  
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2. These clinicians must be involved in prescribing or recommending opioids for 
hospice and/or palliative care patients. 
3. These clinicians must understand English. 
4. All participants must be willing to be interviewed. 
Summary 
This study used a qualitative description method to explore hospice and palliative 
care clinicians’ opioid prescribing practices as they relate to the opioid epidemic and 
associated policies. A qualitative descriptive study offers a method that may elucidate 
clinicians’ perceptions of opioid prescribing and how these practices might have changed 
related to the opioid epidemic. It is the belief of the study author that contextualization of 
the phenomena would be best explored by interviewing those responsible for opioid 
prescribing. The study was guided by use of the TPB, a theoretical framework that can 
help explain intention to prescribe opioids. The study helps address a significant gap in 
the existing literature. Findings may help characterize prescribing patterns, beliefs, and 
concerns, among hospice and palliative care clinicians and identify possible unintentional 




OPIOID EPIDEMIC AND PRESCRIBING IN HOSPICE AND PALLIATIVE CARE:  




Context: Rising rates of opioid abuse worldwide have led to implementation of policies 
to curb opioid prescribing. It is unknown what impact these policies currently have on 
prescribing within the setting of hospice and palliative care.   
Objectives: To determine the current state of the science of opioid prescribing in hospice 
and palliative care related to the opioid epidemic and related policies.  
Methods: A systematic integrative literature review was conducted using the Cumulative 
Index of Nursing and Allied Health Literature (CINAHL), PubMed, ProQuest Central, 
and SCOPUS. 
Results: A total of 54 studies were found in this review. A majority of the existing 
literature examines physician perspectives related to opioid prescribing in primary care 
settings. Ample evidence exists that policies can and do affect rates of opioid prescribing 
in primary care. Evidence suggests that opioids are necessary in hospice and palliative 
care to help manage pain.  
Conclusion: Research is necessary to examine the possible impact of the opioid epidemic 





Recent decades have seen rising rates of opioid addiction, related overdoses, and 
deaths that have reached epidemic proportions (Dasgupta et al., 2014; Manchikanti et al., 
2012). Although rates of addiction and overdose continue to climb, it appears that 
nationally, opioid prescribing reached its peak in 2012, when 81.2 opioids were 
prescribed per 100 people. As of 2017, this number had fallen dramatically, nearly 28% 
to 58.5 opioids prescribed per 100 people (Centers for Disease Control and Prevention, 
2017e). The reason for this decline is likely complex and multifactorial. However, new 
policies and guidelines, and increased regulatory scrutiny are almost certainly influential 
in affecting patient access to prescription opioids and provider prescribing practices.  
Opioids remain a mainstay for treatment of pain for patients nearing end of life 
(Gabbard et al., 2018). In the setting of hospice and palliative care, opioids are primarily 
used for treatment of pain and dyspnea associated with advanced illness or the dying 
process (Blinderman & Billings, 2015). Pain and subsequent opioid use among hospice 
patients is widely prevalent and is ethically grounded in the principal of a pain free death 
(van den Beuken-van Everdingen et al., 2007). Potential unintended consequences of 
policy changes could have a detrimental impact on hospice and palliative care patients by 
limiting access to opioids and increasing the prevalence of untreated symptoms or 
distress (Gabbard et al., 2018; Varilla, Schneiderman, & Keefe, 2015; Wilson, 2017). 
These unintended consequences could ultimately result in increased patient suffering. 
This paper explores the current state of the science of opioid prescribing in hospice and 




An integrative literature review was conducted using the framework established 
by Whittemore and Knafl (2005). An integrative review is particularly useful as it allows 
for the inclusion of studies involving diverse methodologies (Whittemore & Knafl, 
2005). For the purpose of this review, multiple online databases were searched including 
the Cumulative Index of Nursing and Allied Health Literature (CINAHL), PubMed, 
ProQuest Central, and SCOPUS. Consultation was also sought with a health librarian to 
ensure that search terms were comprehensive and not excluding viable databases. 
Keywords and medical subject headings (MeSH) used included palliative care and/or 
hospice; analgesic, opioid; prescribing, substance, and United States. Non-MeSH terms 
primarily consisted of synonyms and included prescribing patterns, analgesics, pain 
management, opioids, palliate, and policy. The terms epidemic and crisis were also 
searched given the frequency and formal use of these terms in referring to the current 
opioid problem. Searches were limited to the past ten years as this time period was felt to 
capture the national peak of opioid prescribing in 2012 and thus possibly reveal studies 
elucidating important trends. Inclusion criteria consisted of original research, related to 
the topic of opioid prescribing, that were published within the past ten years, and written 
in English. Given a limited number of results specific to opioid prescribing in palliative 
care and hospice, a wider search was taken to include articles involving other medical 
specialties, as it was felt that the prescribing practices, perceptions, and barriers of other 
specialties can inform both depth and breadth of the topic. Initially, international articles 
were to be excluded from this search as to better frame the national opioid problem and 
35 
 
its impact on palliative care. However, due to a limited number of results, the search was 
expanded to include international articles, which were felt to be relevant to explain 
prescribing within hospice and palliative care. It is noteworthy that although the United 
States is in the midst of an opioid epidemic, much of the world also has problems with 
opioid use and addiction (Manjiani, Paul, Kunnumpurath, Kaye, & Vadivelu, 2014). 
A keyword search of “palliative care and opioid” revealed 1,756 articles 
published within the past ten years. This was reduced to 132 articles with the addition of 
“prescribing” added to the search criteria. The keyword search of “opioid prescribing and 
palliative care” revealed 130 articles, which was reduced to 86 with the addition of the 
criteria “not review” and further reduced to 19 with the criteria “United States.” The 
same search with “hospice” further located 28 articles. Searching the MeSH terms 
analgesics, opioid and United States located 1,470 articles, which was reduced to 226 
with addition of “prescribing patterns,” and further reduced to 169 with the addition of 
“not review.” A similar search within CINAHL using key words “opioid prescribing,” 
limited to peer review, located 336 articles, most of which were also found in the 
PubMed database. The search criteria within CINAHL was narrowed using keywords 
“opioid prescribing and palliative care” and “opioid prescribing and hospice” and 
“United States,” which located 24 articles. The final number of articles included in this 
review was 54.  
A search within SCOPUS found 96 articles using the above search criteria but 
none were considered relevant or were not previously located via other sources. ProQuest 
Central was used primarily to search dissertations that might be related to the topic. 
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However, no dissertations were found to be directly relevant. Article titles, abstract, and 
full text were screened for relevance and inclusion criteria to include in this review.  
Results 
Opioid Prescribing in Hospice and Palliative Care 
There is a paucity of existing research exploring the specific impact of the opioid 
epidemic on hospice and palliative care clinicians or factors influencing prescribing. Only 
a single article was found directly related to the opioid epidemic and palliative care. A 
majority of related literature regarding the potential impact of the opioid epidemic on 
hospice and palliative prescribing are of case reports and expert opinion and therefore 
were excluded from this review. One study was found that looked retrospectively at the 
morphine equivalent dosing of medications prescribed by oncologists on patients referred 
to a palliative care clinic over six-year period (Haider et al., 2017). The study found that 
opioid dosing had significantly declined over the six years following increased regulatory 
and internal scrutiny. Specifically, from 2010 to 2015, the median daily morphine 
equivalent dosing decreased from 78mg to 40mg. The authors were unable to state 
unequivocally the cause for the decline but suggest it was likely due to increased 
regulations such as additional training required for the prescribing of long-acting opioids 
and review of a prescription drug monitoring program (PMDP) prior to prescribing. The 
authors note that at the time of this study, many of the regulations that were possibly 
influential in affecting prescribing patterns were voluntary and not yet mandated under 
state or federal law (Haider et al., 2017). Similarly, a study by Barbera et al. (2017) 
analyzed prescribing data of opioids between the years of 2009 and 2013 for cancer 
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patients in Ontario, following implementation of a mandatory province-wide pain 
assessment tool. Despite having increased pain assessment at times of patient contact 
with a cancer center and increased reports of pain, the rate of opioid prescribing actually 
decreased by five percent. The authors felt that the likely explanation for the reduced 
rates of opioid prescribing was fear among prescribers given increasing regulatory action 
in an era of the opioid epidemic (Barbera, Sutradhar, Chu, Seow, Earle, et al., 2017).  
Haider et al. (2017) also found that over a six-year period, the type of opioid most 
frequently prescribed changed in relation to regulatory policy. The most frequent opioid 
prescribed was hydrocodone but during the period of time reviewed for the study this 
medication, regulated by the Controlled Substances Act, was rescheduled from schedule 
III (less restrictive) to schedule II (more restrictive). The authors felt that this regulatory 
change likely impacted the transition to tramadol as a preferred opioid for the oncologists 
at MD Anderson Cancer Center (Haider et al., 2017). Similarly, another retrospective 
review of hospital data found a significant reduction in the numbers of hydrocodone 
prescriptions given across a hospital system and a transition to codeine-based opioids and 
tramadol following the 2014 rescheduling of hydrocodone. The authors of this study note 
that regulatory restrictions might have unintentional consequences of transitioning to 
weaker opioids such as increased pain or adverse effects from codeine metabolites 
(Bernhardt et al., 2017). 
A Need for Opioids in Hospice and Palliative Care 
Not surprisingly, studies suggest that palliative care and hospice involvement are 
associated with opioid use (Borgsteede et al., 2009; Childers, King, & Arnold, 2015; 
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Heneka, Shaw, Azzi, & Phillips, 2018). Among cancer patients treated at a nursing home, 
hospice admission was associated with increased prevalence of opioid use when 
compared to patients not admitted to hospice care. However, among these patients, more 
than 60% were found to have pain, possibly indicating undermedication and a continued 
need for opioid access in these settings (Hunnicutt, Tjia, & Lapane, 2017). Conflicting 
data were found looking at a cross-sectional review of the 2004 National Nursing Home 
Survey which suggested that only 30% of nursing home residents admitted to hospice 
care had pain during the prior week and a majority of these nursing home hospice 
patients had access to opioids (75%) (Hanlon, Perera, Sevick, Rodriguez, & Jaffe, 2010).  
Studies reveal that patients with cancer pain are often under medicated with 
opioids, particularly within the last twelve months of life (Barbera, Sutradhar, Chu, 
Seow, Earle, et al., 2017; Fisch et al., 2012; Gao, Gulliford, & Higginson, 2011; Ziegler, 
Mulvey, Blenkinsopp, Petty, & Bennett, 2016). These patients are often involved with 
palliative care. A retrospective chart review was done to find the prevalence of cancer 
patients that reported moderate to severe pain and yet did not receive an opioid. These 
patients were receiving palliative radiation, referred to treatment by oncologists and 
palliative care clinicians. Prevalence of undertreatment ranged from 28% to 40% over a 
period of six years (Kirou-Mauro et al., 2009). A prospective survey of over 3,000 cancer 
patients revealed that 67% had pain and over 30% were not being adequately treated with 
opioid analgesics (Fisch et al., 2012). The same study found that non-white patients were 
twice as likely to receive inadequate opioid dosing, likely related to providers’ implicit 
biases involving opioid addiction and stoicism among minority patients (Fisch et al., 
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2012). A study by Shaheen et al. (2010) found that errors were common in cancer patients 
and could lead to under-prescribing of opioids. 
 The availability, type, and strength of the opioid prescribed in the setting of 
hospice and palliative care is often dependent on the patient’s prognosis and clinical 
trajectory (Borgsteede et al., 2009; Muir et al., 2013). A survey of 425 palliative care and 
hospice patients cared for by primary care clinicians revealed that 37% of patients who 
had a diagnosis of cancer were prescribed opioids three months prior to death and this 
gradually increased to 81% three weeks prior to death. Among non-cancer patients, 27% 
had a prescription for an opioid three months prior to death and this also increased to 
64% of patients with a prescription for an opioid three weeks prior to death (Borgsteede 
et al., 2009). Borgsteede et al. (2009) also found that the potency of the opioid prescribed 
(as defined by the World Health Organization analgesic ladder) increased as the patient 
neared end of life. Similarly, the dosage and frequency of pro re nata (PRN) medications, 
including opioids, was found to increase as patients neared end of life (Russell, Rowett, 
& Currow, 2014). There is also evidence that referral to a palliative care clinic results in 
increased prescribing of long acting opioids (Muir et al., 2013). However, this study had 
a small sample of prescribers in a single palliative care clinic, so opioid changes might 
reflect prescriber preferences that are not generalizable outside that location (Muir et al., 
2013)  
Barriers and Facilitators to Opioid Prescribing in Hospice and Palliative Care 
 Evidence suggests that there are patient and clinician factors that can be a barrier 
to receiving pain management for patients in palliative care (Gardiner et al., 2012; Kwon, 
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Oh, et al., 2013). Gardiner et al. (2012) qualitatively studied provider perceptions to 
barriers involving palliative care. The authors found that many in primary care had fears 
related to prescribing opioids as patients neared end of life. Clinicians were most 
concerned when opioids were requested for the palliation of dyspnea or high dose opioids 
were required for the management of pain. Both palliative care and primary care 
clinicians identified education and experience with opioid prescribing as a potential 
barrier that could limit access. Clinicians who had limited education or experience were 
less likely to be comfortable with prescribing opioids. A theme emerged that primary care 
clinicians working with palliative care could facilitate the best access to opioids and 
specialty management of patient symptoms. Additionally, a barrier of patient and family 
perceptions was identified. Patient or family perception that opioids could cause 
addiction or administration lead to death were barriers to accepting treatment (Gardiner et 
al., 2012). Another study looking at a secondary data analysis and using the Barrier 
Questionnaire II as an instrument, found minimal barriers for patients receiving adequate 
pain management in outpatient palliative care (Kwon, Hui, et al., 2013). The authors 
found that of 196 patients, 96% were on a strong opioid and 63% of these patients were 
satisfied with their pain regimen. The authors suggest that at the time of the study, liberal 
access to opioids for palliative care patients might have resulted in minimal barriers in 
this sample (Kwon, Hui, et al., 2013). A similar study by the same authors but using a 
sample from a Korean hospital system found patient depression as a significant barrier to 
pain management (Kwon, Hui, et al., 2013) 
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 The study by Gardiner et al. (2012) also identified media exposure and national 
discourse as a possible barrier to opioid prescribing among primary care and palliative 
care clinicians in the United Kingdom. The authors detail an example of a famous case of 
a physician serial killer who murdered patients using lethal doses of opioids. Focus 
groups revealed that the case was at the forefront for some clinicians making decisions 
when prescribing opioids. Clinicians worried about increased scrutiny and were more apt 
to rely on specialists such as palliative care to prescribe for patients nearing end of life 
(Gardiner et al., 2012).  
 Cagle et al. (2015) studied the efficacy of an educational intervention on 
alleviating patient and family barriers with opioids in the hospice setting. The 
intervention group showed decreased stoicism (e.g. perception of being viewed as weak), 
knowledge, and reduced barriers to pain management when compared to the control 
group. The authors found that barriers seemed more prevalent in African American 
caregivers, who reported increased stigma and fear associated with opioid administration. 
The intervention seemed particularly efficacious in alleviating these concerns among this 
demographic (Cagle et al., 2015).  
Errors involving opioid prescribing, particularly in cancer patients are frequent 
and can be a barrier to adequate pain management (Heneka et al., 2018; Shaheen et al., 
2010). A study by Shaheen et al. (2010) looked at medication errors in cancer patients as 
a way to support palliative care involvement as expert prescribers, possibly intervening in 
cases where patients were undermedicated. In a prospective survey of 186 cancer patients 
presenting to a palliative care clinic, at least 70% of patients had errors to opioid 
42 
 
prescribing frequency, duration, type, and dosage. Most of the errors found in this study 
(78%) were associated with providers failing to give around the clock opioids for pain 
control. The authors felt these errors could lead to poor pain control and felt that 
palliative care was an effective intervention to ensure appropriate opioid prescribing 
(Shaheen et al., 2010). Heneka et al. (2018) also found medication errors were common 
in both cancer and palliative care. Factors like clinician education or confidence were felt 
to have contributed to opioid prescribing errors (Heneka et al., 2018).   
Setting of palliative care services and type of opioids used were found to be 
possible barriers to effective analgesia in a prospective cohort study in Germany (Müller‐
Busch, Lindena, Tietze, & Woskanjan, 2005). The authors found that patients that 
received palliative care services in the home were more likely to require a switch to a 
new opioid due to uncontrolled symptoms. Similar to other studies, patients with cancer 
were generally found to have poor pain control or were undermedicated. Adverse events 
associated with opioids, although rare, were also identified as a barrier to effective pain 
management (Müller‐Busch et al., 2005). 
Substance Misuse and Addiction in Hospice and Palliative Care 
 Palliative care and hospice clinicians have had to adapt to the opioid epidemic by 
incorporating guidelines and misuse screening into their practices (Childers et al., 2015; 
Merlin et al., 2018; Tan, Barclay, & Blackhall, 2015). Although opioid use might be 
clinically relevant, some patients remain at risk of misuse. However, data conflicts on 
how well or often clinicians perform screening for opioid misuse. Using a retrospective 
chart review, 114 patients at the University of Virginia Palliative Care Clinic were 
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assessed for opioid misuse risk using the Opioid Risk Tool. Authors found clinically 
significant risk with 43% of patients identified as having medium to high risk (Barclay, 
Owens, & Blackhall, 2014). In a national survey of palliative care clinicians who manage 
cancer pain, of 157 respondents, a majority were confident in managing opioid misuse in 
their clinics and routinely practiced risk mitigation strategies such as urine drug 
screening, checking PDMP databases prior to prescribing, and adhering to opioid 
contracts (Merlin et al., 2018). However, another survey of directors of palliative 
medicine fellowships found that although most programs incorporated substance misuse 
training into their curricula, a minority of programs had policies related to the routine 
screening of patients or families for misuse and diversion. Subsequently, use of urine 
drug screening and other risk mitigation strategies was generally infrequent (Tan et al., 
2015). Another study used retrospective chart reviews to assess the prevalence of opioid 
misuse in a palliative care clinic. Although identification of possible opioid misuse was 
frequently identified on assessment, use of risk mitigation strategies was rare. Only four 
percent of 323 patients received a urine drug screen (Childers et al., 2015). Social Worker 
psychosocial assessments for 105 national hospice agencies were evaluated in another 
study to determine the characteristics of substance abuse screening. The study found that 
68% of agencies performed some type of substance abuse screening for patients and 
families, yet the quality and type of these screenings differed by hospice agency (Sacco, 
Cagle, Moreland, & Camlin, 2017).  
 A study by Childers et al. (2012) found significant gaps in the education of 
palliative medicine physicians who were pursuing fellowship training. The study revealed 
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that treatment of opioid misuse was prevalent (77% had treated someone with a substance 
abuse disorder in the previous two weeks) and many reported having active concerns that 
patients were misusing medications. However, few (21%) of the physicians in this study 
felt comfortable with their training or ability to treat the symptoms of these patients 
(Childers & Arnold, 2012).  
External Factors that Influence Opioid Prescribing Outside of Hospice and 
Palliative Care 
 
Implementation of policies. There is research that suggests the implementation 
of policy at the organizational, state, or federal level is effective at reducing opioid 
access, particularly policies to encourage or mandate use of a PDMP database prior to 
prescribing opioids (Baehren et al., 2010; Bao et al., 2016; Gomes et al., 2014). Other 
research has showed inconclusive or limited impact on opioid prescribing following 
implementation of state PDMP programs (Barbera, Sutradhar, Chu, Seow, Howell, et al., 
2017). However, using data from the National Ambulatory Medical Care Survey, Bao et 
al. (2016) showed a 30% reduction in the prescribing of schedule II opioids following 
PDMP implementation in 24 states. Following enactment of PDMP policy in Ontario, 
Canada, opioid prescriptions decreased by 12% in the first six months after 
implementation (Gomes et al., 2014). Kaiser Permanente, a large hospital and insurance 
system in California, saw substantial reduction in the numbers of opioids prescribed after 
implementing a comprehensive program, which included dispensing policies, drug 




Clinician perception of policies. Much of the research into clinician perceptions 
of policies is derived from survey data of primary care and emergency physicians. 
Physicians appear to have mixed views regarding policies aimed to improve the opioid 
epidemic (Click et al., 2018; Cushman et al., 2017; Franklin et al., 2013; Kennedy-
Hendricks, Richey, et al., 2016; Knight et al., 2017; Sinnenberg et al., 2017). A study of 
Wisconsin physicians found that a majority generally had a poor understanding of 
policies affecting opioid prescribing that had recently been implemented in the state 
(Wolfert, Gilson, Dahl, & Cleary, 2010). Kennedy-Hendricks et al. (2016) found that a 
majority of primary care physicians surveyed were concerned with the significance and 
prevalence of the opioid epidemic. Most of the physicians in the study felt that the nature 
of the problem was the responsibility of those with opioid misuse disorders and generally 
supported policies increasing oversight of high-volume prescribers, mandating use of 
PDMP databases, and integration of opioid prescribing into electronic medical records. 
Conflicting views were found by Cushman et al. (2016) through a qualitative study of 
physicians and nurse practitioners. Themes identified prescriber concerns with regulatory 
scrutiny and the barriers of implementing policy such as time required to complete pain 
assessments and check a PDMP database prior to prescribing. Click et al. (2018) also 
found that clinicians generally felt that PDMP databases were a challenge and time 
consuming to use. Franklin et al. (2013) found only 25% of primary care clinicians 
surveyed were concerned about regulatory oversight. However, although a small 
percentage, nearly five percent of nurse practitioners surveyed planned to stop 
prescribing opioids due to regulatory changes. Another study found that 29% of primary 
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care physicians surveyed prescribed fewer opioids as a result of the increased regulations 
(Breuer, Cruciani, & Portenoy, 2010).  
Clinician perception of opioid prescribing. Research suggests that physicians 
have a negative perception of addiction related to the opioid epidemic and subsequent 
opioid prescribing (Franklin et al., 2013; Harle et al., 2015; Hooten & Bruce, 2011; 
Jamison et al., 2014; Kennedy-Hendricks, Busch, et al., 2016; Sinnenberg et al., 2017). A 
survey of Texas family physicians found that attitudes regarding opioids were associated 
with willingness to prescribe. Although a majority of respondents (81%) of physicians 
felt that long-acting opioids would help in controlling chronic pain and would improve 
patient quality of life, a majority (78%) also felt that prescribing long-acting opioids 
would lead to increased regulatory scrutiny. Nearly half (51%) of physicians felt that 
prescribing long-acting opioids would lead to addiction. The study found that physicians 
who identified as being “unwilling” to prescribe long-acting opioids generally had less 
favorable attitudes regarding opioids (Nwokeji, Rascati, Brown, & Eisenberg, 2007). A 
study by Michael et al. (2018) found that clinicians in the emergency department setting 
generally had inaccurate perception of their own opioid prescribing habits and what they 
perceived to be group norms. Once identified, this lack of self-awareness could be 
corrected through intervention by showing the clinician their own prescribing data, which 
often led to reduced future opioid prescribing (Michael, Babu, Androski, & Reznek, 
2018). A survey of clinicians at an academic medical center found that a majority felt that 
opioids were overused and more dangerous than other types of analgesia. This study also 
found that a majority of clinicians surveyed identified patient requests as a significant 
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factor in opioid prescribing and that resident physicians were the group most likely to feel 
pressured to prescribe opioids during the hospitalization (Oyler et al., 2018).  
Knowledge deficits and lack of confidence regarding opioid prescribing are 
identified by clinicians as barriers to opioid prescribing (Franklin et al., 2013; Jamison et 
al., 2014; Pearson, Moman, Moeschler, Eldrige, & Hooten, 2017). Studies conflict in 
their assessment of clinician confidence. Jamison et al. (2014) found that younger 
physicians were more likely to have a knowledge deficit and subsequently lack 
confidence regarding opioid prescribing. Similarly, Pearson et al. (2017) also found a 
majority of clinicians lack confidence in managing chronic pain with opioids. However, a 
survey of primary care providers at the Veterans Health found a majority were moderately 
or strongly confident in their ability to manage chronic pain and prescribe opioids 
(Dobscha, Corson, Flores, Tansill, & Gerrity, 2008). Data show that as clinician 
confidence increases, concerns regarding opioid prescribing decrease (Macerollo, Mack, 
Oza, Bennett, & Wallace, 2014).  
Clinician characteristics. Clinician characteristics such as race, sex, type of 
medical training, and years of experience can significantly influence opioid prescribing  
(Bartley et al., 2015). In the study by Bartley et al. (2015), female practitioners were 
more likely to show willingness to prescribe analgesia, particularly among non-White 
patients. Another study found that clinician authoritarianism, tied to political ideology, 
had an influence on opioid prescribing. Physicians who identified as being highly 
authoritarian were more likely to have negative perceptions of opioid prescribing and 
chronic pain patients. However, despite these negative perceptions and concerns, high 
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levels of authoritarianism was associated with increased rates of opioid prescribing than 
physicians with lower levels of authoritarianism (Burgess, Dovidio, Phelan, & Van Ryn, 
2011).  
The type of medical practice and specialty of the clinician is highly correlated 
with rates of opioid prescribing (Levy, Paulozzi, Mack, & Jones, 2015). In 2012, the year 
that rates of opioid prescribing peaked in the United States, primary care clinicians 
prescribed nearly half of all opioids. From a period of 2007 to 2012, the specialty that had 
the steepest decline (8.9%) was emergency medicine (Levy et al., 2015). Among 
Medicare patients visiting an emergency department between 2008 and 2011, a 
retrospective analysis revealed that despite having similar diagnoses, patients were more 
or less likely to receive opioids based on the physician seen. Physicians could be 
stratified into high prescribing or low prescribing categories, suggesting that physician 
characteristics were more influential than patient characteristics (Barnett, Olenski, & 
Jena, 2017).  
Patient characteristics. Ample research shows that patient characteristics can 
influence a provider’s willingness to prescribe opioids (Burgess, Nelson, et al., 2014; 
Burgess, Phelan, et al., 2014; Fisch et al., 2012; Spitz et al., 2011). Providers may 
perceive age as a barrier to opioid prescribing, particularly with geriatric patients (Spitz et 
al., 2011). A study of analgesia in the emergency department did not show any racial 
disparities with rates of opioid prescribing (Dickason et al., 2015). However, race has 
been shown in other studies to be a barrier to adequate pain management, especially for 
African American and minority patients (Burgess, Nelson, et al., 2014; Fisch et al., 2012). 
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Similarly, diseases with history of societal biases or stigma have been shown to be 
barriers to adequate pain management. This is particularly the case with patients infected 
with human immunodeficiency virus (Lum et al., 2011). The type of pain reported by the 
patient may also be a barrier. Clinicians are more likely to perceive chronic pain 
negatively (Dobscha et al., 2008; Hooten & Bruce, 2011; Wilsey, Fishman, Ogden, 
Tsodikov, & Bertakis, 2008). Despite these barriers, patients may have substantial 
influence over a prescribers willingness to prescribe opioids in the method and frequency 
by which they request prescriptions (McKinlay, Trachtenberg, Marceau, Katz, & Fischer, 
2014). In a qualitative study of patients with chronic pain who access the emergency 
department, many identify feeling pain management and opioid prescribing was a 
fragmented process with poor communication by clinicians who did not always 
incorporate principles of inclusion and shared decision making (Smith et al., 2015). 
Analysis 
The perceptions and beliefs of hospice and palliative care clinicians regarding the 
opioid epidemic are unknown. It is possible that clinicians are experiencing unintentional 
pressures regarding their opioid prescribing from organizations, peers, or changing policy 
similar to what has been identified in other specialties (Hooten & Bruce, 2011; Jamison 
et al., 2014; Kennedy-Hendricks, Busch, et al., 2016; Pearson et al., 2017). However, 
research is needed to explore these perceptions to identify if a problem exists.  
A majority of studies found in this review evaluate the opioid epidemic through 
the lens of a physician as prescriber. Studies that included other types of clinicians (e.g. 
nurse practitioners, physician assistants) had samples where these prescribers were a 
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minority. No study was found that looked at the problem through an interdisciplinary lens 
(e.g. nurse, social worker, chaplain, physician), which is a defining characteristic of 
hospice and palliative care. Hospice is an area that requires strong advocacy from nurses 
to ensure patients receive adequate symptom relief.  Research is needed to understand the 
potential impact of the opioid epidemic on nurses’ ability to fulfill the role of patient 
advocate. When nurses perceive that they are unable to fulfill their duty, it can potentially 
lead to moral distress and affect both clinical outcomes and job satisfaction (Epstein & 
Hamric, 2009). Some nurses may lack confidence or fear administering opioids to 
patient’s nearing end of life (Coyne et al., 2018). It is possible that the discourse 
surrounding dangers of opioids might heighten this fear and lead to poor patient 
advocacy.  
A majority of the studies found in this review were quantitative and used survey 
methodology. A majority of the qualitative studies found relating to opioid prescribing in 
hospice and palliative care were based in Europe. Although many of the factors relating 
to the domestic opioid epidemic are international such as substance abuse, addiction, and 
stigma, these international studies may not be fully representative or transferable to the 
United States. This clearly reflects a research gap.  
Currently, there does not appear to be research exploring the intersection between 
the experience of the hospice or palliative care patient with pain and the evolving opioid 
epidemic. Additionally, research is needed on the experience of the caregiver of a hospice 
or palliative care patient in an era of the opioid epidemic. In the event of unintentional 
consequences to this population stemming from the opioid epidemic, it would be the 
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patients and caregivers who would be best suited to describing the phenomenon and 
consequences.  
Discussion 
The historical perception has been that opioid use for palliative care and hospice 
patients is safe and efficacious when appropriately administered and without significant 
risk of addiction (Pinkerton & Hardy, 2017). However, few studies on opioid safety exist 
in this population given that those patients who are nearing end of life are often excluded 
(Schenker, Merlin, & Quill, 2018). The perception of opioid efficacy and value for 
patients with limited life expectancy is reflected in the national discourse, policies, and 
guidelines. However, increasingly federal and state policies have been enacted, which 
have been shown to reduce opioid prescribing (Bao et al., 2016; Cushman et al., 2017; 
Franklin et al., 2013). Research is needed to identify the possible impact that these 
policies and the shaping culture surrounding the opioid epidemic might have on hospice 
and palliative care.  
 Of the 54 studies found for this review, only a few studies directly address the 
potential impact of the opioid epidemic on hospice and palliative care clinicians and the 
prescribing of opioids in this setting (Haider et al., 2017). Many studies relate to high risk 
patient populations such as oncology instead of hospice or palliative care (Borgsteede et 
al., 2009; Haider et al., 2017; Kirou-Mauro et al., 2009). However, the existing research 
does help elucidate the potential impact of policies that could limit opioid prescribing in 
this population. Research suggests that policies such as implementation of PDMP 
databases are efficacious in reducing opioid prescribing (Bao et al., 2016; Gomes et al., 
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2014). Research also clearly shows that many patients with diseases typically followed 
by hospice and palliative care (e.g. cancer) are often undermedicated and yet continue to 
have pain syndromes requiring access to opioids (Barbera, Sutradhar, Chu, Seow, 
Howell, et al., 2017; Bernhardt et al., 2017; Fisch et al., 2012; Gao et al., 2011). There 
appear to be existing barriers to patients accessing opioids within hospice and palliative 
care (Cagle et al., 2015; Gardiner et al., 2012; Kwon, Hui, et al., 2013). Any policies that 
might further limit pain management to these populations might result in unintentional 
harm through increased pain and suffering.  
It is evident that some clinicians in other settings such as primary care have 
negative perceptions of patients with substance abuse and chronic pain (Click et al., 
2018; Cushman et al., 2017; Wolfert et al., 2010). These negative perceptions and 
policies implemented to combat the opioid epidemic can affect opioid prescribing (Bao et 
al., 2016; Franklin et al., 2013; Gomes et al., 2014). Hospice and palliative care patients 
are often cared for in partnership with clinicians from primary care and other specialties. 
Perspectives from these specialties is important to help develop the breadth needed to 
understand the full impact of the opioid epidemic on hospice and palliative care.  
The lack of existing research into the impact of the opioid epidemic on hospice 
and palliative care has many gaps that need to be filled by research. A first step should be 
a descriptive characterization of the perceptions of those clinicians involved in 
prescribing opioids in hospice and palliative care. A benefit of hospice and palliative care 
is the provision of care using an interdisciplinary team. Research should also contextually 
explore opioid prescribing through the lens of this interdisciplinary framework. Next, 
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research should be undertaken to determine how, when, and why hospice and palliative 
care clinicians decide to prescribe or withhold prescribing of opioids. This information 
should help elucidate factors that facilitate or impede opioid prescribing within the 
context of the current opioid epidemic. Research should also be undertaken to see if there 
are relationships between state and federal policies and the number and type of opioids 
prescribed by hospice and palliative care clinicians. Ultimately research should 
characterize the impact that the opioid epidemic and policies have had on patients within 
the hospice and palliative care setting. This research will take time to develop and would 
occur in a highly dynamic social context with ever-developing policies. However, such 
research is essential to better understand how opioids are used to treat patients that are 
nearing end of life. Ideally such research might be used to help shape future policy, 









This qualitative descriptive study attempted to explore the impact of the opioid 
epidemic and related policies on opioid prescribing in the setting of hospice and palliative 
care. Opioids remain a mainstay for the treatment of symptoms as patients near end of 
life (Borgsteede et al., 2009; Childers & Arnold, 2012; Heneka et al., 2018; Hunnicutt et 
al., 2017). To date, a paucity of research exists exploring the perceptions of hospice and 
palliative care clinicians related to opioid prescribing and no research has been found that 
qualitatively describes this phenomenon as it relates to the opioid epidemic and/or rapidly 
changing polices and regulations. This study aimed to address this important gap in the 
existing health care literature. This chapter will describe the selected study methodology 
and rationale. Methodological decisions will be described including design, sampling, 
data collection, protection of human subjects, data analysis, and steps taken to improve 
the trustworthiness of the data. Potential study limitations will also be discussed.  
Methodology 
 This qualitative descriptive study aimed to answer the following two research 
questions: 1. How has the opioid epidemic and related policies affected opioid 
prescribing practices among hospice and palliative care clinicians; and 2. How do hospice 
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and palliative care clinicians feel patients’ end of life care has been impacted by the 
opioid epidemic and related policies? 
Theoretical Foundation 
Theory should guide the research question, which in turn guides the methodology 
chosen for the study (Creswell & Creswell, 2018). The Theory of Planned Behavior 
(TPB) offers a theoretical framework that conceptually explains the link between the 
intention to act (i.e. the behavior) and the constructs of attitude, subjective norms, and 
perceived control (Ajzen, 1991). This theory has been shown to be useful in predicting 
prescribing behaviors among clinicians (Ali Murshid & Mohaidin, 2017). The major 
theoretical constructs of the TPB provide a conceptual framework to understand how 
prescribing behaviors of hospice and palliative care clinicians can be affected by change 
in attitudes and beliefs. Increased regulatory scrutiny imposed by guidelines or policies, 
and a possible shift in values within the medical community would seem theoretically 
influential as factors that might also affect opioid prescribing among hospice and 
palliative care clinicians. 
The TPB was used in creation of the interview guide.  Questions were 
theoretically framed by the constructs of the TPB. Constructs of subjective norms, 
attitudes, and perceived control should be characterized through participant description of 







 Qualitative description was used to answer the research questions. This design 
offers a method that is well suited for characterizing the phenomenon of interest. 
Qualitative description is less interpretive than other qualitative methods and allowed the 
researcher to stay data near while comprehensively exploring the phenomenon 
(Sandelowski, 2000). The methodological focus is on naturalistic inquiry, which allowed 
study within the hospice and palliative care environment in attempt to describe and 
characterize opioid prescribing (Kim et al., 2017; Sandelowski, 2000). Qualitative 
description is a method that allows thorough description of the phenomenon by those 
experiencing it (i.e. hospice and palliative care clinicians) and should help address gaps 
in the literature (Willis et al., 2016). The method is particularly well suited for 
characterization of a problem (Neergaard et al., 2009). The method is also appropriate for 
research that has limited allocation of time and resources (Bradshaw et al., 2017). In the 
setting of limited previous research, qualitative description can serve as a structure to 
identify clinicians’ perceptions of the opioid epidemic and barriers and facilitators to 
prescribing opioids. Although not explicitly identified, several studies examining topics 
surrounding opioid prescribing have utilized what appear to be qualitative description as 
a method (Click et al., 2018; Fleming et al., 2018; Harle et al., 2015). 
Data Collection 
The study accounted for an emergent design that allowed for change to the 
research process as needed to ensure a thorough exploration and description of the 
phenomenon of interest (Creswell & Creswell, 2018). The study design primarily 
57 
 
consisted of one-on-one face to face interviews between clinicians and the primary 
investigator. Remote interviews using telephone or skype was also considered if 
clinicians were to have difficulty scheduling time for a one-on-one interview. Remote 
interviews may also have been recorded digitally for transcription purposes. Recruitment 
and interviews continued until saturation was achieved. It was expected that some 
participants might be interviewed more than once. The interviews were estimated to take 
approximately one hour or less. The setting for interviews was conducive to audio 
recording and in a mutually agreeable location such as the office space of the clinician, 
library, or coffee shop. Interviews were audio recorded using two digital devices to 
prevent unintentional data loss due to device failure.  
Demographic information was collected including age, sex, type of provider, and 
years of experience, and setting of practice (e.g. inpatient vs outpatient) to characterize 
the sample. An interview guide was used to guide the interview process. Interviews were 
semi-structured to ensure that key and relevant information was gleaned from the 
interview process. However, open ended questions were used to promote a rich narrative 
discussion with hope that the nuanced social context of the factors related to opioid 
prescribing would be elicited. Probing questions were used as a tool for clarification or to 
facilitate conversation. Collectively, questions were asked that would help elicit details 
regarding the clinician’s attitudes and beliefs related to opioid prescribing within the 
setting of hospice and palliative care. The interview guide included the following 
questions, which were asked of each participant: 
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1. In your opinion, how has the opioid epidemic and related policies affected opioid 
prescribing in the specialty of hospice and palliative care? (TPB Concept – 
Attitude) 
2. What factors are barriers or facilitators to you prescribing opioids in hospice and 
palliative care? (TPB Concept - Perceived Behavioral Control) 
3. How would you describe the culture of opioid prescribing within your workplace? 
What about hospice/palliative care in general? (TPB Concept – Subjective Norm) 
4. Do you intend to change your opioid prescribing practices as a result of the opioid 
epidemic and/or related policies? (TPB Concept – Behavioral Intention)  
Additionally, when time permitted, follow up questions were asked, including: 
1. Describe a situation in which you have cared for a hospice or palliative care 
patient that has uncontrolled pain and limited access to opioids. Was this situation 
affected by either the opioid epidemic or related policies? 
2. Are you familiar with the North Carolina STOP Act and the CDC guidelines 
related to opioid prescribing? How might these guidelines impact opioid 
prescribing in hospice and palliative care? 
3. Do you have any advice to other hospice and palliative care professionals 
prescribing in the era of the opioid epidemic? 
Data Analysis 
Data analysis was conducted concurrent with data collection to ensure that 
saturation occurred. Demographic data was collected and analyzed using descriptive 
statistics to characterize the sample. Directed content analysis using Erlingsson and 
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Brysieqicz (2017) framework was used to analyze the interview transcripts. Analysis 
used an inductive focus with in vivo codes in order to capture the participants own 
description of the phenomenon. Content analysis provides an ideal technique by which to 
characterize and describe the data and is commonly used as an analysis method for 
qualitative descriptive studies (Elo & Kyngäs, 2008; Hsieh & Shannon, 2005; Kim et al., 
2017). Content analysis allows a flexible approach that highlights the contextual factors 
that might influence the phenomenon of interest (i.e. opioid prescribing) (Vaismoradi, 
Turunen, & Bondas, 2013). A codebook was created allowing for consistency through the 
coding and analysis process. Coding occurred at the level of the sentence, which helped 
capture the ideas and contexts relayed by the study participants. Codes were clustered 
into categories and subcategories, which were then analyzed for conceptual relationships 
and description of the phenomenon. Findings were presented as major categories using 
exemplars from the coded data to provide descriptive evidence (Hsieh & Shannon, 2005). 
Microsoft Word Suite was used to facilitate data organization and coding (Hahn, 2008).  
Sampling, Recruitment, and Setting 
Inclusion criteria consisted of any physician or nurse practitioner currently 
practicing in a hospice and/or palliative care setting who prescribes opioids. Any 
clinician that had not had a recent (within three months) experience prescribing, 
managing, or consulting on care related to opioids for hospice and palliative care patients 
was excluded. It was not anticipated that any non-English speaking clinicians would be 




 Sampling was purposive using the snowballing technique via professional 
networks. The study was conducted in central North Carolina at organizations that 
provide hospice and palliative care services. Hospice and palliative care clinicians were 
sought after that work in inpatient and outpatient settings.   
Ethical Issues and Protection of Human Subjects 
Approval was obtained from the Institutional Review Board at the University of 
North Carolina at Greensboro. Informed consent was obtained from all participants. 
Confidentiality was maintained given the possible sensitive nature of opioid prescribing. 
Pseudonyms were assigned and used during the data collection to ensure that data were 
not linkable to any specific participant. All organizations represented by the study were 
masked. Sensitive data were aggregated. Data were transcribed using a transcription 
service with confidentiality agreements in place. Data were electronically stored in cloud-
based storage provided by the University of North Carolina at Greensboro while adhering 
to data security protocols.  
Participants of this study each received a $20 Amazon gift card. Incentives are 
frequently used in qualitative research to ensure adequate sampling (Robinson, 2014). 
Although most research regarding clinician-derived incentives have involved ways to 
encourage physician participation in survey methodology, use of incentives in qualitative 
research are felt to be necessary to partially compensate clinicians for their time and 
ensure robust participation (Signorelli et al., 2018). Incentives with clinicians should be 
adequate enough to ensure response (Dillman, Smyth, & Christian, 2014). “Token” 
incentives that offer little value have not been shown to improve response rates among 
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physicians (Field et al., 2002). Use of gift cards of a reasonable amount should provide 
adequate compensation, while avoiding the potential introduction of biases found when 
the value of the incentive encourages research subjects to participate at the expense of 
truthfulness (Robinson, 2014).  
Trustworthiness of the Data (Role of the Researcher) 
A variety of techniques were employed to ensure study validity and reliability 
(Creswell & Creswell, 2018). An audit trail consisting of field notes, memos, and study 
decisions helped ensure credibility. Data were conveyed using rich narrative descriptions 
in the words of the study participants. Rich, thick descriptions are used to describe 
participant narratives to help ensure trustworthiness. Additionally, figures and tables help 
convey the study findings, which also establish trustworthiness (Elo & Kyngäs, 2008). 
Efforts were taken by the primary investigator to be reflexive in his views of the study 
phenomenon as to ensure that undue bias was not introduced during the study.   
Bracketing was used to identify any preconceived biases that may be have been 
held by the primary investigator of this study. Prior to initiating the study, the student 
researcher spent time reflecting on his own perceptions and biases related to the research 
questions. These thoughts were documented and available for reference during the data 








 This study was limited to: 
1. Physicians and nurse practitioners currently practicing within hospice and 
palliative care settings in North Carolina. The limitation to a single state helped 
control for variation in state policies.  
2. These clinicians must have been involved in prescribing or recommending opioids 
for hospice and/or palliative care patients. 
3. These clinicians must understand English. 
4. All participants must be willing to be audio tape recorded/interviewed. 
Summary 
 This study aimed to fill a key literature gap by describing how the opioid 
epidemic and policies have affected opioid prescribing in hospice and palliative care. The 
study used qualitative description as a study design to ensure that contextual factors were 
explored through the attitudes and beliefs of hospice and palliative care clinicians who 
are engaged in opioid prescribing. The Theory of Planned Behavior was used to guide 
this study as it provides an ideal conceptual framework to explain the factors that affect 
intentionality to prescribe opioids. All reasonable methods to ensure ethical standards and 
protection of participants were adhered to throughout this study. Reliability and validity 
were maintained through use of an audit trail, bracketing, and use of an experienced 








 Rates of addiction and opioid abuse have surged in recent decades resulting in the 
U.S. Surgeon General declaring the problem a national epidemic (U.S. Department of 
Health and Human Services, 2018). The opioid epidemic led to enactment of policies at 
the state and federal level to reduce patient access to opioids. Data suggest that these 
policies have been effective at reducing the number of opioids prescribed by clinicians 
(Jones et al., 2018). Examples of such policies include the guidelines introduced by the 
Centers for Disease Control and Prevention (CDC) in 2016 and the North Carolina 
Strengthen Opioid Misuse Prevention (NC STOP) Act of 2017. Collectively, these 
policies place regulatory pressures on prescribing clinicians and discourage use of 
opioids for chronic pain. However, opioids remain a primary method of palliating 
distressing symptoms for patients with complex, life-limiting illnesses, which are often 
managed in the setting of hospice and palliative care (Gabbard et al., 2018). Despite 
policy exclusions for hospice and palliative care patients, it is unknown if these policies 
may have unintended consequences affecting the prescribing practices within these 
specialties.  
 Previous studies such as the one by Haider et al. (2017) found a decline in opioid 
prescribing within a palliative care clinic between the years 2010 to 2015, likely related 
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to increased regulatory scrutiny. Additionally, the same study found the most frequently 
prescribed opioid for palliative care patients in an oncology setting changed to tramadol 
after the rescheduling of hydrocodone-acetaminophen by the Drug Enforcement Agency 
(Haider et al., 2017). Similarly, another study found that opioid prescribing decreased in 
a cancer center in Ontario, Canada, following implementation of a mandatory pain 
assessment tool (Barbera, Sutradhar, Chu, Seow, Earle, et al., 2017).  
 Multiple studies document that clinicians practicing in primary care and other 
specialties frequently have concerns about opioid prescribing and related policies (Click 
et al., 2018; Cushman et al., 2017; Franklin et al., 2013; Kennedy-Hendricks, Richey, et 
al., 2016; Knight et al., 2017; Sinnenberg et al., 2017). However, there is a paucity of 
research currently describing the perceptions of hospice and palliative care clinicians on 
the opioid epidemic and how related policies might influence their prescribing practices 
and clinical decision making. This study aims to help address this important gap in the 
literature by answering the following two research questions: 1. How has the opioid 
epidemic and related policies affected opioid prescribing practices among hospice and 
palliative care clinicians, and 2. How do hospice and palliative care clinicians perceive 
patients’ end of life care has been impacted by the opioid epidemic and related policies? 
Methods 
 A qualitative descriptive, cross sectional design was used to conduct this study. 
Given the focus on naturalistic inquiry, qualitative description is particularly well suited 
for identification of problems and characterizing the phenomena of interest (Willis et al., 
2016).  The Theory of Planned Behavior (TPB) was used as a theoretical framework to 
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guide the research. The constructs of the TPB (attitude, subjective norms, and perceived 
behavioral control) help explain potential factors that can influence behavioral intention 
to prescribe opioids (Ali Murshid & Mohaidin, 2017). The TPB was primarily used to 
guide the creation of the interview guide.  
Study Participants 
This study was approved by an Institutional Review Board. Participants were 
recruited purposefully using professional networks and snowballing. Inclusion criteria 
consisted of physicians and nurse practitioners currently practicing within hospice and 
palliative care settings in North Carolina who had been involved in prescribing or making 
recommendations for opioids within the past three months. Six physicians and four nurse 
practitioners (see table 1) agreed to participate and be interviewed in a location of their 
choosing. Participants were employed in three different agencies in central North 
Carolina and represented a variety of roles in inpatient, outpatient, hospice, and palliative 
care settings.  
Data Collection 
 Semi structured interviews lasting 30 to 60 minutes were conducted with open 
ended questions and follow up probes were used to evoke participant responses. All 
participants were asked their perception of how the opioid epidemic and related policies 
have affected opioid prescribing in hospice and palliative care, to identify factors that 
facilitate or impede opioid prescribing, to describe the culture of opioid prescribing in 
their workplace and specialty, and if they had changed or intended to change their opioid 
66 
 
prescribing due to the opioid epidemic and/or related policies.  Demographic data were 
collected from each participant.  
Data Analysis 
 Interviews were audio recorded and transcribed verbatim for analysis. Content 
analysis occurred concurrently with data collection and continued until saturation was 
reached (Erlingsson & Brysiewicz, 2017). In vivo codes were used to characterize the 
phenomenon using the participant’s own language. A codebook and Microsoft Word 
helped organize the data and facilitate the coding process. Codes were grouped 
inductively into related categories and subcategories. 
Results 
Four primary categories emerged during the analysis, which described the 
reported area of impact of the opioid epidemic and related policies on the patient, 
clinician, nursing, and specialty. Participants universally agreed that the opioid epidemic 
had influenced these four areas within hospice and palliative care, although the perceived 
scope and nature of the impact varied. Variation in perception seemed to differ by 
primary practice specialty (i.e. hospice vs palliative care) and setting (inpatient vs 
outpatient).  
Impact on the Patient 
 All participants reported encountering patients that had poor pain control or 
limited access to opioids due to the opioid epidemic. Most participants used words like 
“serious pain,” “terrible pain control,” and “suffering” to describe these patients. The 
following statement seems to summarize the general sentiment among the group, “So, 
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patients who are nearing end of life, who may also have very heavy chronic disease 
burdens, they have to fight to get pain control. We see it time and time again.” 
Additionally, half of the study participants felt that patients were being overly 
stigmatized or victimized in some way due to the opioid epidemic. Most of the stigma 
surrounded labeling by other members of the health care team with phrases like “drug 
seeker” or “drug addict” when patients verbalized pain complaints or requested opioids. 
Many participants spoke of encounters with patients where they had difficulty 
appropriately prescribing opioids due to patient or family fear of addiction. A majority of 
participants also identified experiences or concerns that patients would turn to illicit 
opioids due to uncontrolled symptoms.  
 
We also have people who are using illicit drugs to control their pain because they 
can't get, uh, drugs in legal ways. They're taking it out of their relative's closet or 




Impact on the Clinician 
 While study participants readily identified and spoke of the impact of the opioid 
epidemic on their patients, a majority stated that there had been few changes made to 
their individual prescribing practices related to the opioid epidemic or policies. Most 
participants identified strong personal beliefs related to the need for opioids in this patient 
population. Additionally, participants seemed to have the perception that their practices 
were safe and would continue despite a change in the practice behaviors of surrounding 
clinicians and the medical culture at large. However, half of the participants spoke of the 
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need to incorporate protocols and careful prescribing practices due to the opioid 
epidemic. Use of prescription drug monitoring programs, risk assessment tools, pain 
contracts, urine drug screens, and having an exit strategy were all identified as practices 
currently utilized by study participants to prescribe opioids in hospice and palliative care. 
Phrases like “I prioritize symptom management” and “I did it anyway” were used to 
characterize their willingness to continue prescribing. Some participants noted the 
iatrogenic nature of the epidemic but felt that their prescribing within the setting of 
hospice and palliative care did not contribute to the problem and therefore should not be 
subject to change.  
 
I really don't look at [the epidemic] as a barrier. I mean there's a place for if it's 
indicated, its needed, I write it. I don't worry about, no, I don't worry about an 
epidemic and don't worry about any of that stuff because then you're going to 
maybe not give it to someone who needs it. 
 
 
Impact on Nursing 
 Many participants spoke of nurses acting as strong advocates for effective pain 
control despite the perception that other members of the health care team often engaged 
in patient labeling and limited opioid prescribing. However, a majority of participants 
also discussed issues with perceived inappropriate nursing practices that resulted in 
patients not being administered opioids when needed. One participant stated: 
 
I'm not getting any PRNs given and I'm walking in seeing somebody breathing 40 
times a minute. I'm seeing a real lack of education no matter how many times I 
stress opioids are not just for pain. This is for this dyspnea. It's written on the 




Another participant expressed: 
 
It's very distressing for the nurses when people can't get medicine that they think 
that they should get. Um, and you know, and I think that they're willing to try 
alternatives and do whatever. But I do think, um, they feel, they feel that they're 
the patient advocates. 
 
 
In analyzing participant responses, it appears that the practice setting was 
particularly influential in the perception of nurses as patient advocates or contributors to 
the problem of poor symptom control. Participants who worked in the inpatient setting 
more often experienced problems with as needed medications not being given 
appropriately. Conversely, participants who worked in the community setting or hospice 
more often perceived nurses as patient advocates.   
Impact on the Specialty 
 A majority of study participants reported feeling that the opioid epidemic had 
limited impact on patients within the hospice setting but that they had seen more impact 
within palliative care. Phrases like “the safest environment” and “victims are not hospice 
patients” were used to describe hospice as being marginally impacted by changes 
resulting from the opioid epidemic and policies. One participant described it this way, 
“People who go into hospice feel that end of life needs to be comfortable, whatever that 
takes and that it often requires opioids, so I do think that opioids are prescribed. I just, I 
don't think it's changed.” 
 Unanimously, study participants described organizational problems stemming 
from the opioid epidemic as having impacted inpatient and outpatient hospice and 
70 
 
palliative care. Primarily these problems arose from concerns with clinicians in other 
medical specialties. In the inpatient setting, participants often described having problems 
with hospitalists refusing to prescribe. Oncologists were also frequently identified as 
clinicians who were reluctant to prescribe opioids. One participant told of a patient with 
an advanced malignancy who presented to the hospital with an acetaminophen overdose 
due to a refusal from the oncologist to prescribe opioids. Another participant described an 
oncology group that no longer prescribes opioids and instead refers all patients for pain 
management to palliative care. Hospice clinicians also described being asked by referring 
clinicians to take over opioid management. 
 Palliative care clinicians were more likely to describe a lack of resources as a 
primary barrier to opioid prescribing. Clinicians in the inpatient setting described 
concerns with opioid management when there was no outpatient clinician willing to 
assume the responsibility upon discharge.  One participant described it in the following 
way, “Can I find an oncologist, primary care physician, pain management specialist, 
somebody who feels comfortable enough or understands enough what my intent was to 
continue that whenever they leave here?” 
The palliative care clinicians in the community also identified organizational 
structure as a primary barrier. These consulting clinicians engaged in opioid 
recommendations to the referring clinician and did not assume primary prescribing 
responsibility. They described frequent “push back” from the referring provider that 
might be unwilling to start or adjust a patient’s opioid regimen. Other participants 
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identified leadership concerns and a perception that they were not supported by their 
supervisors in the prescribing role.  One participant described the following: 
 
I was flat out told by my boss, you cannot do this. I'm telling you you can't do 
this. And I even said to him, you're telling me how to practice medicine? And he 
said, well, in this case I am. 
 
 
Some participants voiced a belief that the broad definition of palliative care was a 
challenge in the setting of the opioid epidemic. Phrases like “we don’t know how to 
label” and “so it all goes to palliative care” describe these concerns. Other palliative care 
participants in both inpatient and outpatient settings, described an increased number of 
referrals for pain related issues due to an unwillingness by other clinicians to prescribe. 
One participant described it this way: 
 
I think in the palliative care space that changes have occurred, completely. You 
know, palliative care services had been one of those first doors in which people 
with opioid addiction had been knocking on to, to, to see if they could get this 
ongoing prescribing because of PCPs have shut down the doors. 
 
 
A majority of participants also identified regulatory factors related to the opioid 
epidemic as influential to the specialty of hospice and palliative care. Most clinicians 
were able to describe the CDC guidelines and NC STOP Act and knew that hospice and 
palliative care were excluded from many of the regulatory criteria. However, a majority 
of participants described the impact on outside medical specialties as still reverberating 
within hospice and palliative care. Many participants used the metaphor of the “swinging 
pendulum” to describe concerns related to policy. One participant expressed it this way: 
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It has a, just because it has become such a national issue and, and, and you know 
that it's being tracked, you know, that it's being monitored. And so sometimes that 
has become a determining factor for people within the field of hospice and 
palliative care. And what are the end outcomes of that? Do you think it becomes 
harder to do, to do the right thing if a, uh, you know, this is a gonna have such 




 This study focused on clinician’s perceptions of the impact of the opioid epidemic 
on hospice and palliative care. All participants in this study had seen an impact on their 
patients due to the opioid epidemic, although, hospice seemed less affected than palliative 
care. Most participants seemed to value the use of opioids for managing distressing 
symptoms in patients with complex and life-limiting illnesses. Despite being regulatorily 
excluded from many of the provisions outlined in the CDC guidelines and NC STOP Act, 
participants in this study describe unintended consequences resulting from the shift in the 
medical culture away from opioid prescribing. It is clear that these study participants do 
not view hospice and palliative care as working in a disciplinary silo, insulated from the 
forces affecting the outside medical community. As primary care providers, oncologists, 
and other medical clinicians grow increasingly reluctant to prescribe opioids, it has a 
ripple effect reaching those vulnerable patients with life limiting illnesses. Participants 
voiced that these changes led to limited access to opioids, poor pain control, and patient 
suffering.  
 All study participants identified organizational and structural concerns due to the 
opioid epidemic that impacted their practices. Problems involved lack of resources, 
perception of increased risk among other clinicians, and a lack of leadership support. Of 
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the various barriers to opioid prescribing identified in this study, factors at the 
organizational level might be those that are best suited to intervention. Implementation of 
prescribing protocols using opioid risk assessment tools, drug monitoring programs, and 
pain contracts can be implemented in hospice and palliative care to help ensure safe 
prescribing. Education and training can be performed with clinician staff to ensure that 
they understand policy and the role of opioids in managing distressing symptoms for 
patients nearing end of life. Additionally, educational strategies can be employed with 
department leaders to ensure that they are able to nimbly react to the changing opioid 
landscape and support their clinicians in providing evidence-based treatment.  
 Regulators should understand the broad impact of opioid policies even in the 
setting of specialty exclusions. Several participants voiced concern that future polices 
could more directly target patients in hospice and palliative care. One participant felt that 
palliative care was particularly vulnerable to oversight given the broad nature in which 
some health care organizations define the scope of the specialty. However, it seems 
imperative upon leaders within the specialty to advocate and lobby for reasonable and 
safe opioid prescribing policies that mitigate the potential unintended consequences of 
further limiting patient access to these medications.  
 More research is needed to further characterize clinician’s perspectives and 
determine the impact of the opioid epidemic and related policies on hospice and palliative 
care patients. The qualitative design and localized sampling used in this study might limit 
transferability. A future study might nationally survey hospice and palliative care 
clinicians to gain a wider perspective on the potential impact of the opioid phenomenon. 
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 The purpose of this study was to descriptively examine the opioid prescribing 
practices among hospice and palliative care clinicians as these practices relate to the 
opioid epidemic and associated policies. This research used a qualitative descriptive 
design. Ten participants, who represented three different hospice and palliative care 
organizations within central North Carolina were interviewed using an open ended, semi-
structured approach. Analysis of the data revealed four primary categories: (1) Impact on 
the Patient; (2) Impact on the Clinician; (3) Impact on Nursing; (4) Impact on the 
Specialty. These categories were subcategorized into 12 areas that descriptively 
characterized the participants’ narratives. Many of the subcategories were interrelated. 
For example, “undertreatment” was particularly impactful to the patient and it was in part 
perceived to be affected by subcategories that were impactful to the clinician, nursing, 
and/or specialty (e.g. “Limited  Changes Made to Individual Prescribing,” “Inappropriate 
Nursing Practices,” and/or “Regulatory Influence”). This chapter will explore the 
significant findings from the study as they relate to the previous literature, hospice and 
palliative care, nursing practice, education, theory, policy, and future research. Study 




Significant Study Findings 
Impact on the Patient  
All participants in this study perceived patients as having been impacted by the 
opioid epidemic and/or related policies. The category of “Impact on the Patient” was 
subcategorized into areas that highlighted the nature of that impact. Subcategories 
consisted of “Undertreatment: Poor Pain Control/Limited Access to Opioids,” 
“Stigma/Victimization,” “Illicit Use,” and “Fear.” 
Undertreatment: Poor pain control/limited access to opioids. Universally, 
participants voiced having experienced patients with undertreatment from either limited 
access to opioids or poor pain control. This experience is perhaps best illustrated through 
the following quote by a participant:  
 
We have, uh, seen at least one or two...Tylenol overdoses because, uh, these 
severe cancer pain patients had no access to, um, safely getting the right type of 
medications that they need. So they just took as much as they needed of whatever 
they could get their hands on. So GI bleeds from excess NSAID use is getting 
common, Tylenol overdoses are getting common. And then the stigma on top of 
all of this that now they're labeled, uh, you know, overdose patients, and now they 
have a psych consult to help determine capacity and, you know, how, how much 
below dignity can, can these people, you know, go, uh, as they're battling, uh, you 
know, serious life limiting illness. That's what's at stake here. 
 
 
The implications of this statement are profound. The participant clearly characterizes 
harm befalling patients due to limited access from opioids in patients managed under an 
inpatient palliative care model. The existing literature provides limited data upon which 
to compare these findings. However, there does exist data that supports the 
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undertreatment of pain specifically in cancer patients (Fisch et al., 2012; Haider et al., 
2017; Kirou-Mauro et al., 2009).  
Limited access to opioids or reduced opioid dosing in patients with severe cancer 
pain syndromes would suggest undertreatment. It is not reasonable to generalize the 
above participant’s experience of acetaminophen overdose with a phenomenon that 
extends outside the hospital and region in which the clinician practices. However,  these 
findings are particularly disturbing considering the existing guidelines that support the 
use of opioids in managing oncologic pain (P. J. Wiffen, Wee, Derry, Bell, & Moore, 
2017). Opioids remain the centerpiece of the World Health Organization’s pain ladder 
and are recommended for mild, moderate, and severe pain with the goal of achieving 
freedom from cancer pain (World Health Organization, n.d.-b).  
Stigma/victimization. The subcategory of “Stigma/Victimization” describes 
participants perceptions that other members of the healthcare team have implicit biases, 
stigma, or have engaged in labeling of patients due to the opioid epidemic. This 
subcategory also reflects the view of a minority of participants, that patients are being 
directly victimized as a result of the opioid epidemic or changing policies. Although, just 
a few participants detailed experiences of victimization, the phenomenon seemed 
particularly impactful to the patient experience. This is perhaps best described by the 
following quote from a participant: 
 
These patients can become victims as well, you know? Um, especially when you 
decrease the supply on the outside, like when patients can't, you know, chronic 
pain patients, even substance abuse patients can't get what they need, treatment 
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for their addiction. I mean, sometimes these patients can even become targets, like 
victims, so people will steal their meds or replace her meds. 
Participants seemed especially keen to identify stigma when a patient  
 
unintentionally overdosed on an opioid or was identified by the healthcare team as being 
“drug seeking.” Participants stated that these biases among the healthcare team led to an 
unwillingness among clinicians to prescribe or administer opioids. One participant 
described labeling in this way, “It’s stigma is what it is. The drug seeker is inherently a 
bad patient…it's not a medical term and we should stop using it.”Stigma as it relates to 
opioid prescribing and patients with a history of addiction has been well documented in 
the literature (Buchman, Leece, & Orkin, 2017; Bulls et al., 2019).   
Illicit use. The subcategory of “Illicit Use” was described as a concern for a 
majority of the study participants. Some study participants identified having experienced 
patients with addiction and abuse of opioids. However, a majority of participants seemed 
to perceive illicit use as a byproduct of undertreatment of pain or limited access to 
opioids due to the opioid epidemic, changing policies, and restricted prescribing by other 
clinicians. The phenomenon of illicit use was perhaps best described by the following 
participant: 
 
We also have people who are using illicit drugs to control their pain because they 
can't get, uh, drugs in legal ways. They're taking it out of their relative's closet or 








Another participant described it in this way: 
 
People will become drug addicts. People will shoot themselves. I mean, you 
know, if you've got incredible pain, you're gonna find a way to get out of pain and 




 Concerns regarding the illicit use of opioids by patients have been identified in 
studies examining clinician prescribing (Franklin et al., 2013; Kennedy-Hendricks, 
Richey, et al., 2016; Knight et al., 2017). However, these studies involved specialties 
outside of hospice and palliative care. Additionally, the clinicians in these studies 
characterized illicit use as a barrier to their individual prescribing and seemed to view 
their patients through a critical lens. Contrary to this perspective, the participants in this 
study viewed illicit use of opioids as a phenomenon that occurred in part due to 
prescribers’ unwillingness to treat pain with opioids. Clinicians stated that they were 
concerned that undertreatment would increase the prevalence of addiction and illicit 
opioid use. One participant characterized her fears by stating: 
 
So, my concern is it's a true pain. They've had it for a while, that they're not going 
to get [opioids]. It'll just [boom] you'll get cut off. And could that drive you to, 
could that drive you to buy something from another source, get a product off the 
street, relapse on alcohol? I mean, unmanaged pain drives people to, to, to places 
they never thought they would be. That's my, my biggest fear now. 
 
 
 Fear. The subcategory of “Fear” describes clinician perception that patients or 
families have heightened concerns related to opioid prescribing due to the opioid 
epidemic and/or policies. Fear and concerns among patients and caregivers has 
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previously been documented as a barrier leading to undertreatment of symptoms (Chi, 
Demiris, Pike, Washington, & Oliver, 2018). However, this previous study did not 
explore if patient and caregiver fears were exacerbated by the opioid epidemic.  
Primarily, study participants identified media sources as being influential in 
increasing patient fear of opioids. Participants verbalized patient or family fear as a 
barrier to their prescribing opioids in some cases. This fear could impact patients by 
leading to undertreatment of pain and other distressing symptoms. One participant 
described it in this way: 
 
So, it's been this flip culture too, unexpected, unintended consequences where 
patients are saying, I don't want to be addicted. That's a hard one. Or family say 
don't give them that, you know, because they've heard, you know, how horrible 
Oxycontin is on TV. 
 
 
Another participant characterized patient and family concerns in the hospice setting:  
 
The people are all exposed, some of them, like us, have heard, over and over the 
crisis in the nation about opioid addiction, opioid deaths. So obviously as I said 
before, even sometimes when I think maybe we could try some opioids, there may 
be some barriers into utilizing them when I think perhaps could be useful. And 
again, I'm saying perhaps, um, fears of addiction, fears of uh, hasting death. 
 
 
Impact on the Clinician 
The category of “Impact on the Clinician” describes the participant’s perceptions 
of how the opioid epidemic and related policies have directly impacted their own opioid 
prescribing. This category was further divided into two subcategories, including “Limited 
Changes Made to Individual Prescribing” and “Careful Prescribing/Use of Prescribing 
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Protocols”. As this is the first known study to qualitatively describe the perceptions of 
hospice and palliative care clinicians related to the opioid epidemic, there does not exist a 
body of literature with which to directly compare the significance of the study findings.  
Limited changes made to individual prescribing. A majority of the study 
participants indicated that they felt they had not changed their own opioid prescribing 
practices due to the opioid epidemic and policies. One participant had this to say about 
the opioid epidemic: 
 
I really don't look at it as a barrier. I mean there's a place for [opioids], if it's 
indicated, its needed, I write it. I don't worry about, no, I don't worry about an 
epidemic and don't worry about any of that stuff because then you're going to 
maybe not give it to someone who needs it. 
 
 
Participants universally spoke of how the unwillingness of other clinicians to 
prescribe opioids would impact their patients. Some participants discussed feeling 
insulated within hospice and palliative care and therefore did not feel a need to change 
their own prescribing. Some also spoke of the unknown of practicing in other specialties 
and that they thought it possible that they too would be influenced by the same factors 
limiting opioid prescribing if they were practicing in primary care or another medical 
specialty. Comparatively, the existing literature suggests that many clinicians practicing 
in specialties other than hospice and palliative care perceive that they have changed their 
opioid prescribing practices related to the opioid epidemic and/or related policies 
(Franklin et al., 2013; Jamison et al., 2014). It is also noteworthy that there is evidence 
that self-perception of prescribing practices can be inaccurate (Michael et al., 2018). 
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Careful prescribing/use of prescribing protocols. Although a majority of study 
participants did not perceive that their own prescribing practices had changed as a result 
of the opioid epidemic, half described the importance of careful prescribing and/or the 
need to use prescribing protocols in hospice and palliative care. Participants suggested 
use of prescription drug monitoring programs (PDMP), risk assessment tools, pain 
contracts, and ongoing monitoring using pill counts and urine drug screens. Despite many 
participants suggesting that prescribing protocols should be in place, it is not clear how 
often these practices occur. One study found that screening policies and risk mitigation 
strategies were rarely practiced in a palliative care clinic (Tan et al., 2015). A participant 
in this study described their clinical approach for opioid prescribing in inpatient palliative 
care this way: 
 
So I think through continued research and using very reasonable, in my mind, 
approaches to risk stratifying things like an opioid risk tool prior to prescribing 
medications, using things like a urine drug screen, uh, for followup of those, you 
know, um, concerns about misuse, looking at the, the prescription monitoring 
programs before any scripts are given. Um, simple safety things like assessing 
who's in the home. Um, what is the past history of substance use either for the 
individual or family members. 
 
 
Impact on Nursing 
 Study participants often discussed the role of nursing in facilitating or acting as a 
barrier to effective pain management in hospice and palliative care. Collectively, these 
perspectives describe the influence of the opioid epidemic and related policies on 
nursing. The category of “Impact on Nursing” was divided into two prevalent 
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perspectives forming the subcategories of “Inappropriate Nursing Practices” and “Nurses 
as Patient Advocates.”  
 Inappropriate nursing practices. Inappropriate nursing practices were identified 
universally among those clinicians who work in inpatient settings. Primarily, clinicians 
described nurses as being fearful of opioids and therefore reluctant to administer as 
needed doses when patient were symptomatic. This resulted in a change in clinician’s 
management of pain and often required scheduling of the medication. One participant 
described it in the following way: 
 
I think that part of the, the cultural shift is coming particularly with newer nurses, 
is like a phobia of giving people even appropriate doses of pain medications, um, 
because of their perceived, you know, possible bad side effects of it…I'm more 
seeing patients who have ordered as needed medications, not getting them at the 
point that I feel would probably be the point that I would administer that 
medication. There's a lot of clinical judgment that goes into that. I think that's why 
it's still important to continue to, to educate providers that are at the bedside. 
 
 
Participants also commonly identified a perception that staff nurses lacked 
appropriate education and training in opioid management and that this knowledge deficit 
led to inappropriate medication administration. Another participant stated: 
 
I'm not getting any PRNs given and I'm walking in seeing somebody breathing 40 
times a minute. I'm seeing a real lack of education no matter how many times I 
stress opioids are not just for pain. This is for this dyspnea. It's written on the 
orders to give on either, but I'm not getting them given 
 
 
Participants also suggested that issues with administration of as needed medications 
seemed to vary based on the level of nursing experience or the nursing unit. Both attitude 
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and unit location have been shown to affect the willingness of the nurse to administer as 
needed medication (Youngcharoen, Vincent, & Park, 2017). Research has also shown 
that nurses can fear hastening death in patients that might be nearing end of life in the 
acute care setting (Howes, 2015). 
 Nurses as patient advocates. In a 2018 position statement, The American Nurses 
Association reaffirmed the need for nursing advocacy in ensuring that patients receive 
appropriate pain management to avoid suffering (American Nurses Association, 2018a).  
A majority of participants in this study described the role of nurses as advocating for 
appropriate pain management. This advocacy was recognized even by participants who 
also described problems with some nurses adhering to the plan of care when 
administering as needed medications. However, nurses as patient advocates seemed to be 
a more prominent description from participants who worked in community palliative care 
and hospice. One participant, a hospice physician, spoke of the role of nurses as 
advocates and how they perceived those nurses to feel when they encountered barriers to 
proper pain control: 
 
They look at someone and they say, this person’s in pain or this person, you 
know, needs something. And they're told, you know, no they're not. I mean, that 
denigrates their profession to, be able to, to have to hear that. And you know what 
they all say is they get these 20-minute lectures about, you know, what you think 
is pain is not really pain. And so, then that ends up affecting their workday as 
well. And I think sometimes they don't want to call people because they're afraid 
they're going to get this lecture. 
 
 
Another participant also spoke of how they perceived nurses to feel when those nurses 
were unable to obtain proper pain relief for their patients: 
86 
 
It's very distressing for the nurses when people can't get medicine that they think 
that they should get. Um, and you know, and I think that they're willing to try 
alternatives and do whatever. But I do think, um, they feel, they feel that they're 
the patient advocates. 
 
 
Impact on the Specialty 
Study participants universally described the opioid epidemic and related policies 
as having an impact on hospice and palliative care. However, the characterization of this 
impact varied based on the practice setting and type of clinician (hospice vs palliative 
care). The impact on the specialty was further categorized into four subcategories 
including: “Limited Impact Within Hospice,” “Organizational Problems: 
Leadership/Resources/Other Specialties,” “Determination of Patient 
Appropriateness/Referrals, and “Regulatory Influence: Protections versus Pressures.”  
Limited impact within hospice. Most study participants felt that hospice had 
been relatively sheltered from the impact of the opioid epidemic and related policies, at 
least compared to other medical specialties. Participants widely reported using opioids 
within hospice to manage patients’ end of life symptoms. One of the participants in this 
study held a leadership position within a hospice organization and did suggest a view that 
opioids were over prescribed within hospice and that symptoms near end of life might be 
a normal physiological process with limited evidence to support the use of opioids to 
ameliorate distress. However, these views did not seem reflective of the majority of 
participants in this study. This participant also described an internal audit that found 
nearly 100% of patients within their hospice had access to opioids. This finding mirrors 
research that suggests that use of opioids is prevalent within the hospice setting 
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(Borgsteede et al., 2009; Childers et al., 2015; Heneka et al., 2018). One participant 
described use of opioids in hospice in the following way, “People who go into hospice 
feel that end of life needs to be comfortable, whatever that takes and that it often requires 
opioids. So, I do think that opioids are prescribed. I just, I don't think it's changed.” 
Participants suggested that opioids were culturally part of hospice care and that 
had not changed due to pressures from the opioid epidemic. One participant phrased it 
this way: 
 
And to some degree, uh, if you were to look into our population, 100% of our 
patients get an opioid, even if there's no, perhaps evidence that there was a need 
for it. So that cultural ingrained that opioids, uh, was a vehicle that was safe, 
necessary and pain was a real objective and manageable problem, which we call 
the fifth vital signs, that also was part of the hospice culture.  
 
 
However, another hospice physician interviewed felt that there had been some increased 
scrutiny resulting from the opioid epidemic but that the impact had been minimal. They 
described it in the following way: 
 
Obviously, the opiate epidemic is not meant for [hospice], but we do feel the 
ramifications of it cause we just can't hilly nilly write buckets full of medications. 
It still has to be indications to us to say, this is the plan. Is it working? Are they 
following it? And also when we, even in our own roles, we have tightened it. Uh, 
but we're not, we're not, not giving it because we worry about an epidemic. 
 
 
 Some clinicians working in the hospice setting described an organizational policy 
where they were encouraged to have the clinician referring a patient to hospice (i.e. 
primary care) continue prescribing opioids while the patient was enrolled in hospice 
services. Hospice clinicians described receiving “push back” from the referring clinicians 
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who wanted them to take over opioid prescribing. One participant described it in the 
following way: 
 
I mean just a number of times that suddenly the primary care person would say, 
oh they're hospice now. I'm not prescribing it now… I can refer to another hospice 
and, and they'll write these medicines. Why don't you write the medication? So 
that's the other thing that makes me think that it was a little bit organizational. 
And again, the piece I don't understand, is it organizational from high 
administration or is it coming from the supervisor? 
 
 
Limited impact within hospice: Barriers. Universally, study participants felt 
that organizational problems caused barriers to opioid prescribing within hospice and 
palliative care. The most common barriers described were a lack support among 
leadership, limited resources, and problems among other specialties that impacted 
hospice and palliative care patients. Although most clinicians felt that hospice as a 
specialty had limited impact due to the opioid epidemic, a few clinicians identified 
significant problems within their hospice workplace. These problems appeared to be 
associated with lack of leadership support or an organizational culture that did not 
facilitate opioid prescribing. It is unclear if these problems reflect a broader shift in 
hospice prescribing culture or if they were just associated with the hospice organizations 
used in this study. Previous research has shown that prescribing culture and training 
background can be perceived as influential in opioid prescribing practices (Pomerleau, 
Schrager, & Morgan, 2016).  
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One physician described being told by her supervisor that she could not prescribe 
to a particular patient despite feeling like it was clinically prudent. She appeared to have 
some moral distress related to this problem and described it in the following way: 
 
So, the attending wouldn't prescribe [opioids] and [my supervisor] said, you 
cannot prescribe this. You know, he flat out said you can't do it, period. Amen. 
So, the man never got any more of that and we ended up doing a lot of Ativan, 
things like that, but really nothing ever worked. And then at the very end, I did 
end up giving him some Roxanol… I was flat out told by my boss, you cannot do 
this. I'm telling you you can't do this. And I even said to him, you're telling me 
how to practice medicine? And he said, well, in this case I am. 
 
 
All the participants of this study universally identified problems that arose from 
the involvement of clinicians in other medical specialties and the general reluctance of 
these clinicians to prescribe opioids. This finding alone perhaps highlights the 
interconnectedness of hospice and palliative care patients and clinicians to the complex 
nature of the healthcare system. Hospice and palliative care patients are not fully 
insulated by the influential factors that affect opioid prescribing practices within the 
healthcare system at large. Although patient might be followed by hospice and palliative 
care clinicians, these patients still often rely on outside specialties for opioid prescribing. 
Primary care was commonly identified in this study as being a specialty where clinicians 
were particularly reluctant to engage in opioid prescribing. The literature suggests that 
primary care clinicians have concerns associated with prescribing opioids for chronic, 
non-cancer pain (Breuer et al., 2010; Franklin et al., 2013; Jamison et al., 2014; Knight et 
al., 2017).  
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One participant described it in this way, “We have difficulty getting providers in 
the community to even prescribe for them at all.” Other participants described 
oncologists as being reluctant to prescribe opioids: 
 
People who have metastatic cancer related pain and, uh, there's nobody to write 
those medications for these patients. Um, a lot of times even the cancer centers 
are, um, referring these people to pain medicine specialists, uh, to go get their 
opioids from their primary care providers have just about stopped altogether and 
even oncologists have stopped. 
 
 
Yet another participant had this to say about the reluctance among oncologists to 
prescribe opioids: 
 
You have a partner entire health system who not a single oncologist in the 
practice will prescribe opioids. So, it all goes to palliative care. Every single 
opioid prescription that goes out at that cancer center is done by Palliative care. 
 
 
 Study participants who work in inpatient palliative care frequently identified 
problems with hospitalists and a general unease surrounding opioid prescribing. Palliative 
care clinicians are often consultants in the hospital and therefore the primary clinical 
decision making is the responsibility of the referring clinician, often the hospitalist. Study 
participants spoke of making recommendations regarding opioid prescribing that were 
not always agreed upon by other members of the medical team. Study participants also 
spoke of making changes to the opioid regimen in the hospital but not having the 
resources outside the hospital to facilitate post discharge pain management. One 




Like I can't get the hospitalists to continue the medicine, even if we get consulted 
for symptom management. So, say I go in there and I do make you better. Who's 
gonna pick it up from there? I can't get them into a pain clinic. If your primary 
care office isn't going to prescribe it because they're all, you know, imagining all 
this liability, you're not imagining them. Sure. But they're, you know, fearful of 
all this liability and addiction and problems and patients. Um, it's, it's, I, I think 
it's, it's a real problem. 
 
 
Determination of patient appropriateness/referrals. Most study participants 
suggested that they had seen an influx in referrals due to the opioid epidemic. In the case 
of hospice, clinicians described receiving referrals earlier and with an expectation by the 
referring clinician that hospice would take over management of the opioids. Palliative 
care clinicians described receiving an increased number of referrals for pain management. 
These referrals were described as being difficult for clinicians working in community 
palliative care, as they did not assume the responsibility of prescribing opioids, which 
was often the nature of the referral. One nurse practitioner interviewed described it this 
way: 
 
I think as a palliative provider, I think that, you know, the focus has shifted from 
one direction to the other, whether it's chronic disease management and 
preventing hospitalizations to symptom management and focus specifically on 
pain. Sometimes that's physician's easy, their easy way out of saying, okay, well 
we'll just get somebody to come to your house and talk to you about pain 
management and they can deal, you know, help you sort those things out, which is 
great. But you know, then the patients don't quite understand that you're not going 
to hand them a prescription. 
 
 
Some participants identified the broad nature of palliative care as being 
potentially problematic to opioid prescribing. These participants questioned how to best 
determine the appropriateness for patients who would be followed by palliative care and 
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thus who would be regulatorily excluded from policies designed to curb opioid 
prescribing. Hospice clinicians did not seem to have this concern as hospice is better 
defined prognostically for patients limited to six months or fewer of life expectancy. One 
participant described it in the following way, “Where do you kind of draw them line and 
sort of what patients are palliative, which patients are really in more of a chronic pain 
management situation?” Another participant described this concern: 
 
I mean there is good evidence, cancer related pain is well treated by opioids. 
There is not that same evidence to support a lot of these chronic pain things that 
these people have been on opioids. So just relabeling it as a palliative care and 
continue with a medication that's not been proven to be beneficial, I think will 
lead to more regulatory issues in the future. 
 
 
Regulatory influence: Protections versus pressures. The literature 
overwhelmingly suggests that policies have been influential in reducing the number of 
opioids prescribed in outside specialties (Bao et al., 2016; Barbera, Sutradhar, Chu, 
Seow, Earle, et al., 2017; Bernhardt et al., 2017; Breuer et al., 2010; Click et al., 2018). 
However, there exists limited literature that specifically evaluates the impact of policy on 
hospice and palliative care. A majority of study participants described changes in policy 
related to the opioid epidemic as having an impact on the specialty of hospice and 
palliative care. The regulatory influence was characterized as either offering protection or 
creating pressures for opioid prescribing in the specialty of hospice and palliative care. 
One participant described the regulatory protections offered to hospice and palliative care 
in the following way, “The guidelines specifically exclude palliative care and they use the 
word palliative care. Um, so, um, I feel like I personally and professionally and protected 
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because I have a board certification in palliative care.” Another participant described the 
regulatory pressures from policy in the following way, “The STOP Act. Sounds pretty 
scary, doesn't it? Like the STOP Act, you know, stop prescribing is the message I get 
from that, but I'm not going to stop prescribing.” Yet another participant also described 
the impact of regulatory policy acting as a barrier to opioid prescribing in the specialty of 
palliative care.   
 
People have posted on social media where in certain states, even hospice and 
palliative providers have received letters from Medicare or from CMS, uh, saying 
that, uh, their name has come up as one of the highest prescribers and, uh, 
informing them about the perils of the opioid crisis. And, uh, you know, they do, 
they haven't even looked that these are hospice and palliative providers. That's 
why they're writing for what they're writing. So they're getting official letters…it 
has, just because, it has become such a national issue and, and, and you know that 
it's being tracked, you know, that it's being monitored. And so sometimes that has 
become a determining factor for people within the field of hospice and palliative 
care. And what are the end outcomes of that? Do you think it becomes harder to 
do, to do the right thing if, uh, you know, this is a gonna have such unwarranted 




 This study aimed to describe the impact of the opioid epidemic and related 
policies on prescribing practices and end of life care in the setting of hospice and 
palliative care. The findings help fill an important gap in the existing literature. The 
implications of this study are potentially far reaching, affecting a variety of areas in 





Hospice and Palliative Care 
 The findings of this study suggest that the opioid epidemic and related policies 
have had a substantial impact on patients, clinicians, and the specialty of hospice and 
palliative care. Hospice was described as being less impacted than palliative care. 
However, despite policy exclusions, this study suggests that there are still vulnerable 
patients with life limiting illnesses that are undertreated or have reduced access to 
opioids. All participants in this study seemed to recognize and value opioids as a tool 
instrumental in alleviating pain and suffering for those patients with severe or life 
limiting illnesses managed under hospice and/or palliative care.  
 This study provides evidence that hospice and palliative care exist within the 
broader medical community and are therefore impacted by any policy changes that affect 
these outside medical specialties. Palliative care clinicians interviewed for this study 
spoke of the referral and consulting nature of the specialty and a need for cooperation 
with other medical clinicians to ensure that patients had access to opioids. Clinicians 
working in the inpatient setting frequently relied on hospitalists to recognize the need for 
consultation of palliative care and to adhere to recommended changes in the opioid 
regimen. These inpatient palliative care clinicians also spoke of the difficulty in 
transitioning care after the patient discharged from the hospital. A lack of community 
resources for both inpatient and outpatient palliative care led to patients relying on 
primary care providers to assume responsibility for prescribing opioids. Unfortunately, all 
too often this reliance on outside specialties resulted in reports of undertreatment.  
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Particularly troubling is the reported trend by multiple study participants of a 
growing reluctance among oncologists to prescribe opioids. Oncology is a specialty that 
often results in palliative care referral (Courteau, Chaput, Musgrave, & Khadoury, 2018). 
One study participant spoke of an entire oncology group that no longer prescribed opioids 
as a policy and instead referred only to palliative care for opioid management. Other 
studies have also shown a trend of under prescribing among cancer related patients 
(Haider et al., 2017). Despite these changes, opioids remain a mainstay for the treatment 
of cancer pain (World Health Organization, n.d.-b). It is unclear what role palliative care 
might have in the future for the management of oncologic pain as the medical community 
continues to adapt to the opioid epidemic.  
Study participants clearly perceive opioids as an important tool in the 
armamentarium needed to combat distressing symptoms in patients with life-limiting 
conditions. It is important that clinicians working in the specialty advocate for patients to 
receive these medications, if there is clinical indication and the ability to safely prescribe. 
Hospice and palliative care clinicians can also use their expertise to help ease the 
concerns of clinicians in outside specialties that might be fearful to prescribe opioids. It 
appears that the specialty of hospice and palliative care will continue to have an 
important role in the utilization of opioids for vulnerable patients. This study identified 
several gaps in existing community resources that should be addressed. The development 
of future community hospice and palliative care programs should consider the problem of 
opioid access and how the specialty can facilitate prescribing to those patients most in 




 This study highlights the involvement of nurses in pain management in both 
hospice and palliative care. The study findings suggest that nurses maintain a strong 
sense of advocacy in helping facilitate opioid prescribing for patients enrolled in hospice. 
This advocacy is aligned with the interdisciplinary role encouraged by the American 
Nurses Association in the era of the opioid epidemic (American Nurses Association, 
2018a, 2018b). Participants spoke of hospice as being rooted in a historical culture that 
empowered nurses to help shape the pain management needs of patients. One physician 
discussed acquiescing to the requests of the nurse for opioids in an attempt to be 
perceived as the “good hospice doctor” even if he did not feel opioids were clinically 
indicated. However, other participants described the perceived moral distress that nurses 
encounter when they face barriers in obtaining opioids for symptomatic patients at end of 
life. These nurses seemed duty bound to obtain relief for patients despite facing clinicians 
who were reluctant to prescribe opioids. Describing how nurses navigate and respond to 
these challenging inquiries was not an aim of this study. However, nurses’ perceptions 
should be explored in future research given the importance of the role in helping to shape 
the pain management plan in the hospice setting.  
 This study also revealed concerns, primarily among inpatient palliative care 
clinicians, of nurses engaging in inappropriate practices surrounding the administration of 
opioids. Nurses were described as often being reluctant to administer as needed opioids 
for patients with distressing symptoms. Clinicians perceived nurses as being fearful of the 
effects of opioids. Biases and stigma were also mentioned as possible factors leading to 
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inappropriate nursing practices. Clinicians described the need to adjust their prescribing 
due to nurses failing to appropriately administer ordered opioids. The observations of 
nursing practices in the hospital seem contrary to the advocacy reported by nurses in the 
community. These experiences are curious and likely speaks to organizational and 
cultural differences between the practice settings. However, given that nurses were not 
interviewed in this study, not enough data exists to fully describe their role in this 
phenomenon.  
Nursing Education 
Several of the participants in this study perceived nursing and medical staff as 
needing additional education regarding opioid prescribing and appropriate administration. 
Participants related feeling that nurses in particular were fearful of opioids and that 
education might improve their confidence, eliminating a barrier to treatment. Similarly, 
participants implied that physicians in outside medical specialties were over emphasizing 
the risks associated with prescribing and that this fear might come in part due to how 
these clinicians were trained.   
Professional education has been a strategy used to respond to the opioid epidemic. 
The National Academy of Medicine and partner organizations have called to expand 
training in medical schools on opioid prescribing and techniques to respond to the opioid 
epidemic (National Academy of Medicine, n.d.). Similarly, the American Association of 
Colleges of Nursing (AACN) has set a goal to train 15,000 nursing students and faculty 
on opioid prescribing practices and bring awareness to more than 60,000 stakeholders 
regarding the opioid epidemic. Through this call to action, 44% of nursing schools in 
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North Carolina have pledged to teach the Centers for Disease Control and Prevention 
(CDC) guidelines related to opioid prescribing (American Association of Colleges of 
Nursing, n.d.). The expansion of professional education in response to a national 
epidemic is laudable. However, the context of this education has potential to shape 
clinical practice among future and current clinicians. It is unclear if these schools of 
nursing and medicine will emphasize the exclusions found in the CDC guidelines for 
opioid prescribing within hospice and palliative care.  
The AACN has also recommended increased training in palliative care for nursing 
students (Zolot, 2016). Historically, palliative care was not emphasized within the 
training curricula for nurses and other health professions (Wee & Hughes, 2007). 
Additionally, many nurses report a lack of confidence and training in hospice and end of 
life care (Bassah, Seymour, & Cox, 2014). How schools of nursing and medicine deliver 
palliative care content, particularly as it relates to the opioid epidemic should matter 
greatly in the confidence of these clinicians when they enter practice.  
Education should continue to play an important role in addressing the opioid 
crisis. However, educators need to ensure that content is grounded in evidence and not 
delivered in a way that creates fear or bias in those tasked with prescribing opioids. As 
was suggested by study participants, training should ensure that clinicians feel 












This study used the Theory of Planned Behavior (TPB) as a guiding framework 
and for creation of the interview guide. The TPB has been shown to be useful in 
predicting those factors that are influential to behavior such as prescribing medications 
(Ali Murshid & Mohaidin, 2017). The constructs of the TPB (attitude, subjective norms, 
and behavioral control) influence intentionality making behavior more or less likely to 
occur (Ajzen, 1985, 1991; Montano & Kasprzyk, 2015). 
 The findings of this study are theoretically congruent with the TPB as a predictive 
model of prescribing behavior. The study reveals a variety of factors that participants felt 
would either increase or decrease the prescribing of opioids in hospice and palliative care. 
Patient enrollment in hospice, nursing advocacy, and policies that insulated the clinician 
from regulatory scrutiny were all described as facilitating opioid prescribing. Factors that 
were described as barriers to opioid prescribing included workplace culture, stigma, fear, 
lack of community resources, lack of leadership support, an organizational structure that 
prohibits prescribing, and policies that were overly restrictive.  
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The study findings can be categorized by related TPB constructs. For example, 
most of the participants’ perceptions regarding patient impact (e.g. undertreatment, 
stigma, illicit use, and fear) involve the evaluation and beliefs of behavioral outcomes 
(i.e. opioid prescribing), which would align with the TPB construct of “Attitude.” The 
impact on the clinician would align with the constructs of “Behavioral Intention” and 
“Perceived Behavioral Control.” Participants generally described feeling that they had 
not, nor would they change their prescribing practices due to the opioid epidemic or 
related policies. This belief involves “Behavioral Intention” to continue prescribing 
opioids within hospice and palliative care. Participants also described use of prescribing 
protocols and careful prescribing as a way that the opioid epidemic had impacted the 
clinician. Use of prescribing protocols align with the TPB construct of “Perceived 
Behavioral Control” or those factors that affect a participants’ perception of facilitating or 
impeding the behavior (Ajzen, 1985, 1991; Montano & Kasprzyk, 2015).  
 The impact on nursing was subcategorized into “Inappropriate Nursing Practices” 
and “Nurses as Patient Advocates.” Both of these subcategories seem to align with the 
TPB construct of “Subjective Norms.” Subjective norms are the beliefs and perceptions 
of how others view the behavior. Participants seemed to categorize nurses in a 
dichotomous fashion as either being fearful of opioids or strongly advocating for their 
use.  
The impact on the specialty involved subcategories that could be classified into all 
three main antecedent constructs of the TPB (Attitude, Subjective Norms, and Behavioral 
Control). The perception of “Limited Impact Within Hospice” from the opioid epidemic 
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is both an evaluation of outcomes (Attitude) and also describes the social norms 
(Subjective Norms) among peers within the hospice specialty. Similarly, “Organizational 
Problems” reflects both the “Subjective Norms” of peers, leadership, and organizational 
culture. “Organizational Problems” also involves “Perceived Behavioral Control” as 
participants identified many barriers such as lack of resources and problems with other 
specialties that affect the perceived power of the clinician to prescribe opioids. The 
subcategory of “Determination of Patient Appropriateness/Referrals” involves the study 
participants’ evaluation of the outcomes (TPB construct of Attitude) inherent from the 
problem and behavior. Finally, the subcategory of “Regulatory Influence” is most closely 
aligned with the TPB construct of “Perceived Behavioral Control” as it involves 
regulatory factors that are perceived to either insulate the prescriber within the specialty 




Table 5.1 Relation of Major Study Findings to Theoretical Constructs 
 
Categories Subcategories Theory of Planned Behavior Constructs 
 
Impact on the 
Patient 
Undertreatment: Poor pain 
control/Limited access to opioids 
 
Evaluation of Outcomes 
(Attitude) 
Stigma/victimization Belief about Outcomes 
(Attitude) 
 
Illicit use Belief about Outcomes 
(Attitude) 
 
Fear Belief about Outcomes 
(Attitude) 
 
Impact on the 
Clinician 











Inappropriate nursing practices Subjective Norms 
Nurses as patient advocates Subjective Norms 
Impact on the 
Specialty 
Limited impact within hospice 
 
Subjective Norms AND 







Perceived Power (Perceived 
Behavioral Control) AND 
Subjective Norms 
Determination of patient 
appropriateness/referrals 
 
Belief about Outcomes 
(Attitude) 
Regulatory Influence: protections vs 
pressures 
 






 Study participants described policy as being either restrictive or protective given 
the nature of the clinical practice specialty. Most participants cited hospice and palliative 
care as being specifically excluded from opioid prescribing restrictions in the CDC 
guidelines and the North Carolina Strengthen Opioid Misuse Prevention (NC STOP) Act 
of 2017. Given these exclusions, participants felt that they generally had limited 
individual risk prescribing opioids. However, some participants identified the broad way 
in which palliative care can encompass patients across an illness continuum, as being 
potentially problematic in how the specialty is excluded from regulatory restrictions. 
Guidelines frequently recommend palliative care consultation early in the course of an 
illness, while a patient still plans to pursue curative therapy (Courteau et al., 2018). Given 
the broad scope of palliative care, study findings suggest that these patients are more 
likely to encounter outside medical specialties that are involved in opioid prescribing. It 
appears to be these outside specialties that are at most risk of undertreatment, given the 
regulatory pressures applied through policy. This finding is mirrored in the literature that 
suggest restrictive policies can decrease opioid prescribing (Baehren et al., 2010; Bao et 
al., 2016; Gomes et al., 2014). 
 This study suggested that policy exclusions for hospice and palliative care were 
an important factor in ensuring that clinicians within the specialty felt comfortable 
prescribing opioids. Although palliative care can be broadly defined, it is important that 
the specialty continue to receive regulatory exemption from the restrictions commonly 
found in policies designed to curb opioid prescribing. Specialty organizations such as the 
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National Hospice and Palliative Care Organization (NHPCO), Center to Advance 
Palliative Care (CAPC), American Academy of Hospice and Palliative Medicine 
(AAHPM), and the Hospice and Palliative Nurses Association (HPNA) all should 
continue to support lobbying, education, and research to advance policies that protect 
vulnerable patients within hospice and palliative care.   
Study Limitations and Future Research 
 There are several important limitations to this study. First, this study used a 
sample in Central North Carolina. Although three different hospice and palliative care 
organizations were represented, it is unclear if the study findings reflect the perceptions 
of hospice and palliative care clinicians employed in other organizations or other 
geographical regions in the state and country.  Future research should aim to address this 
by reproducing the study using a sample from a broader geographical area (i.e. multiple 
states). Additionally, a mixed methods study using survey design would allow for 
quantitative exploration of the phenomenon, while still retaining the rich contextual data 
offered through qualitative methods. Survey design would also provide a means through 
which to determine if the opioid epidemic and related policies are perceived by a national 
sample to be affecting opioid prescribing within hospice and palliative care.  
 Hospice and palliative care are inherently interdisciplinary. The findings in this 
study support the interconnectedness of hospice and palliative care to other members of 
the healthcare team. Study participants spoke of the role of nurses in facilitating or 
impeding the access of opioids for vulnerable patients. However, staff nurses were not a 
primary focus of this study. Future research would benefit from inclusion of nurses and 
105 
 
other interdisciplinary team members to help elucidate what impact the opioid epidemic 
is having on their roles as they care for hospice and palliative care patients. Additionally, 
future research might also include the perspective of hospice and palliative care patients 
as they navigate through a healthcare system that has increasingly limited access to 
opioids. The perspective of patients and their caregivers would provide invaluable insight 
into the true impact that the opioid epidemic and related policies are having on their 
symptom management and quality of life.  
 As with all qualitative research, the potential for bias may limit the creditability 
and trustworthiness of the data. In the case of this study, an effort was taken to limit bias 
through self-reflection, auditing, memoing, and use of faculty for review. Authenticity of 
the data was maintained through purposeful, flexible sampling and a focus on the 
richness of the data through the analysis process. Additionally, authenticity was 
facilitated through content analysis and use of in vivo coding, which helps ensure that 
study participants’ perceptions are accurately represented (Neergaard et al., 2009; 
Saldaña, 2016).   
 As a method, qualitative description has a notable limitation given its usual lack 
of a theoretical framework and limited use of inference in the analysis process 
(Neergaard et al., 2009; Sandelowski, 2000). These factors are typically limited or absent 
given the descriptive nature of the research method. For this study, a theory was used to 
provide a contextual framework from which to develop the interview guide and interpret 
the findings. The Theory of Planned Behavior is well suited to help understand how and 
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why factors can lead to a change in the prescribing of opioids in hospice, palliative care, 
and related medical specialties.  
Conclusion 
This is the first known study using qualitative description to explore the impact of 
the opioid epidemic and related policies on opioid prescribing in hospice and palliative 
care. This study suggests that the opioid epidemic and related policies have had an 
unintended impact affecting patients, clinicians, nursing, and the specialty of hospice and 
palliative care. Although participants perceived hospice as being less impacted than 
palliative care, all participants spoke of unintended consequences leading to the 
undertreatment of patients.  
This study found that generally there was a perception that hospice had been less 
affected by the opioid epidemic and related policies than palliative care. Participants that 
spoke of undertreatment or limited access within hospice generally described a lack of 
support among leadership and workplace culture as primary causative factors. However, 
all participants agreed that opioids were necessary within hospice to manage symptoms at 
end of life. These findings are consistent with prior research suggesting that opioids are 
still widely used within hospice (Borgsteede et al., 2009; Childers et al., 2015; Hanlon et 
al., 2010; Heneka et al., 2018; Hunnicutt et al., 2017).  
This study suggests that despite regulatory protections for palliative care, patients 
are experiencing unintended consequences of policy as clinicians become increasingly 
hesitant to prescribe opioids. This problem appears compounded by the broad nature in 
which palliative care can apply to patients across a disease trajectory. Palliative care 
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patients often rely on clinicians in other specialties for pain and symptom management 
and are therefore vulnerable to a shift in the broader medical community as opioid 
prescribing becomes less frequent. Perhaps most troublesome, is the consistent report 
among many of the study participants that oncology patients have had increasing 
difficulty accessing opioids to manage their symptoms. The quality of evidence is 
strongest to support use of opioids for cancer related pain and symptoms at end of life 
(Lorenz et al., 2008). However, other research also finds a growing trend of reduced 
opioid prescribing and undertreatment of pain among oncology patients (Barbera, 
Sutradhar, Chu, Seow, Earle, et al., 2017; Fisch et al., 2012; Haider et al., 2017; Kirou-
Mauro et al., 2009; Shaheen et al., 2010).  
This study helps address an important gap in the literature by describing the 
hospice and palliative care clinicians’ perceptions of how the opioid epidemic and related 
policies are influencing opioid prescribing within the specialty. Although this study 
suggests an impact leading to limited access of opioids, increased stigma, and fear among 
some clinicians, the barriers to prescribing opioids were primarily perceived as involving 
related medical specialties. More research is needed to explore this phenomenon. 
Although policy is necessary to respond to the large scope of the opioid epidemic, policy 
makers should be cognizant of the potential for unintended consequences affecting 
vulnerable patients with life limiting illnesses. Opioids seem likely to remain a mainstay 
for the management of symptoms in hospice and palliative care. However, as the broader 
medical community shifts away from opioid prescribing, care must be taken to ensure 
that hospice and palliative care patients still receive access to needed medications. The 
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relief of human suffering at end of life must be prioritized in the development of future 
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Questions asked of all participants: 
1. In your opinion, how has the opioid epidemic and related policies affected opioid 
prescribing in the specialty of hospice and palliative care? (TPB Concept – 
Attitude) 
 
2. What factors are barriers or facilitators to you prescribing opioids in hospice and 
palliative care? (TPB Concept - Perceived Behavioral Control) 
 
3. How would you describe the culture of opioid prescribing within your workplace? 
What about hospice/palliative care in general? (TPB Concept – Subjective 
Norm) 
 
4. Do you intend to change your opioid prescribing practices as a result of the opioid 
epidemic and/or related policies? (TPB Concept – Behavioral Intention)  
 
 
Follow up questions: 
1. Describe a situation in which you have cared for a hospice or palliative care 
patient that has uncontrolled pain and limited access to opioids. Was this situation 
affected by either the opioid epidemic or related policies? 
 
2. Are you familiar with the North Carolina STOP Act and the CDC guidelines 
related to opioid prescribing? How might these guidelines impact opioid 
prescribing in hospice and palliative care? 
 
3. Do you have any advice to other hospice and palliative care clinicians prescribing 































3. What type of medical/nursing license do you have? (Please circle the best option) 
• Physician 
• Nurse Practitioner 
• Physician Assistant 
 
4. What is the primary location of your practice? (Select all that apply) 
• Hospital 
• Outpatient Hospice 
• Inpatient Hospice 
• Inpatient Palliative Care 
• Outpatient/Community Palliative Care 
• Clinic 
• Nursing or Assisted Living Facility 
• Other (Please Explain) 
 
5. How many total years have you been in practice as a physician/nurse 
practitioner/physician assistant? (Please write the appropriate answer using 
numerical value) 
 
6. How many total years have you been in practice in the setting of 












Research Study:  The Opioid Epidemic and the Impact on Opioid Prescribing in Hospice 
and Palliative Care: A Qualitative Description 
 
Investigator:  Joshua Borders, DNP, NP-C, ACHPN, PhD Candidate  
 
Faculty Advisor:  Dr. Susan Letvak 
 
Purpose of the Research Study: This study aims to describe the perceptions among hospice and 
palliative care clinicians of opioid prescribing associated with the opioid epidemic and related 
policies.  
 
Risks: It is possible that the interview could prompt an emotional distress (rare, less than 
1%) related to opioid prescribing, policies, or patient care. If you experience emotional 
distress, you should take a short break, talk with the investigator, or withdrawal from this 
study. If you continue to have emotional distress, you should seek professional help from 
your primary care provider or the local Crisis hotline (1-877-626-1772). Confidentiality 
breach is the second risk (rare <1%). To minimize risk the researcher will not collect any 
identifiable information. Data will be aggregated to protect your confidentiality. 
Pseudonyms will be used to analyze data and in publication. The investigator will only 
share non identified responses with the Faculty Advisor, unless required by law. The 
investigator will keep interview transcripts and field notes in a secured digital file. 
Demographic data will be destroyed once the investigator and the advisor have reviewed, 
summarized, and checked for accuracy. Only the summary information will be retained 
on a password protected and firewalled personal computer, with a backup on the UNCG 
server space for faculty advisor review and validation. 
 
Benefits: Research will help fill the current knowledge gap of opioid prescribing related to the 
opioid epidemic in hospice and palliative care.  
 
Time Required: It is estimated that this interview will take less than 60 minutes. You may be 
contacted in the future to participate in a second interview or to clarify responses from the first 
interview. You may opt not to be contacted for future participation.  
 
Confidentiality: The information that you provide in this study will be handled confidentially. 
No private or identifiable information will be collected. Strategies to avoid this risk are noted 
above under RISKS. 
 





Right to Withdraw: You have the right to withdraw from the study at any time. You 
may do this by informing the principal investigator. 
 
Future Contact: You have the right to opt out of any future contact from this researcher. 
 
Payment: You will receive a $20 Amazon gift card for participation in this study.  
 
If you have questions about the study, please contact:  Joshua Borders, DNP, NP-C, 
ACHPN, PhD Candidate, University of North Carolina at Greensboro, 
jrborder@uncg.edu, 336-264-6762, or Dr. Susan Letvak, 336-256-1024. 
If you have any concerns about your rights, how you are being treated, or if you have 
questions, want more information or have suggestions, please contact:  Office of 

































APPENDIX D  
 
SAMPLE CODE BOOK 
 
 
Categories Subcategories Code Descriptions 
and Data Sample 






access to opioids 
 
Codes refer to the 
perception of the 
clinician that patients 
have improperly 
controlled pain or 
limited access to 
opioids 
 
“So, patients who are 
nearing end of life, 
who may also have 
very heavy chronic 
disease burdens, they 
have to fight to get 
pain control. We see 
it time and time 
again.”  
 
“first seen by me for 
Palliative care and, 
uh, was under 
inadequate pain 
management for his 
metastatic to bone 
pain.”  




they can't be honest 
fight to get pain 
control 
sub optimal regimens 




we can't get rid of 
their pain totally 
in pretty serious pain 
their pain is under 
treated 





Codes refer to the 
identification of 
labels assigned to the 
patient by the 
healthcare team, 
implicit bias, stigma, 
or victimization of 




stereotypes of opioid 
addiction 
the drug seeker is 
inherently a bad 
patient 
have a label 
anywhere on their 





“It’s stigma is what 
it is. The drug seeker 
is inherently a bad 
patient…it's not a 
medical term and we 
should stop using it.” 
 
“they were looking 
at him as someone 
who was potentially 
there to divert 
medications, to use 
some for ulterior 
gain, uh, that he had 
to sit in to room 






Potential for abuse 
drug addict 
divert medications, to 
use some for ulterior 
gain 





Codes refer to the 
illicit use of opioids 
by patients to 
achieve pain relief or 
the processes of 
addiction 
characterized by the 
clinician 
 
“We also have 
people who are using 
illicit drugs to 
control their pain 
because they can't 
get, uh, drugs in 
legal ways. They're 
taking it out of their 
relative's closet or 
they're having 
unusual urine drug 
screens because 
they're so desperate 
for this relief.”  
 
“People will become 
drug addicts. People 







substance abuse and 
chronic pain 
chewing up their 
fentanyl 
they're getting it on 
the streets 





themselves. I mean, 
you know, if you've 
got incredible pain, 
you're gonna find a 
way to get out of 
pain and it's gonna 
be, you know, heroin 
or suicide or 
something. And to 
me, that's not 
justifiable.” 
Fear The codes refer to 
fear or concerns that 
patients or families 
have related to 
opioid prescribing 
 
“So, it's been this 




patients are saying, I 
don't want to be 
addicted. That's a 
hard one. Or family 
say don't give them 
that, you know, 
because they've 
heard, you know, 
how horrible 
Oxycontin is on 
TV.”  
 
“they also have their 
ears have heard 
about the opioid 
crisis and how it 
truly has ruined lives 
and they understand 
that.”  
I don't want to be 
addicted. 
ruined lives 
I don't want to get 
addicted 
fears of addiction, 







Limited Changes Made 
to Individual Prescribing 
 
Codes refer to the 
perception of the 
clinician that their 
individual 
prescribing patterns 
have not been 
significantly 
impacted or changed 
due to the opioid 
epidemic or related 
policies. 
 
“I have zero fear 
from the STOP Act. 
It does not impact 
my practice. Zero. 
Um, I don't think 
about it. I don't 
consider it. I know it 
exists and I know 
what it says, but I 
also at the end of the 
day, feel pretty 
secure in how I 
prescribe opioids and 
under the 
circumstances that I 
prescribed them” 
 
“I mean I think as far 
as prescribing what I 
would prescribe, it 
hadn't changed that, I 
mean starting people 
on opioids, I can 
only speak to what I 
would've done. And 
I think I would, it 
hasn't really 
changed” 
I have very few 
barriers 
zero fear from the 
STOP Act 
it hasn't really 
changed 
I didn't personally 
feel like I was 
contributing 
I wrote prescriptions 
all the time 
I did it anyway 
I do what I feel like I 
need to do 
I prioritize symptom 
management. 
Careful prescribing/Use 
of prescribing protocols 
Codes refer to 
identification of 





that relate to safe 
opioid prescribing 
 
“you need certain 
things in place to 
make sure that safe. 
So you need some 




“looking at dosages 
and for whatever 
reason like pill 
counts have become 
a much more 
important qualifier in 
the minds of some 
physicians whenever 
they're writing.” 
opioid risk screening 
tool 
things in place to 
make sure that safe 
an exit strategy 
physicians have 
contributed to the 
problem 
thoughtful about how 
we prescribed 
assessment of risk 







Codes refer to the 
perception of the 
clinician that nursing 






patients, I think, 
who, um, maybe 
cognitively or are 
verbally unable to 
ask for PRN, like as 
needed medications 
don't get it. That's 
upsetting.” 
 
“I think that part of 
the, the cultural shift 
is coming 
particularly with 
newer nurses, is like 
PRN…medications 
don't get it. 
pill counts 




they do give a lot of 
pushback 
don't even get a PRN 
medications 




a phobia of giving 
people even 
appropriate doses of 
pain medications, 
um, because of their 
perceived, you 
know, possible bad 
side effects of it.”  
Nurses as patient 
advocates 
Codes refer to the 
perception of the 
clinician that nurses 





some long acting 
pain medication, uh, 
not a bad thing. Um, 
so I'm seeing more 
and more, uh, nurses 
being empowered, 
ask for that kind of 
thing and to hold the 
orders accountable 
for what's happening 
with the patient. So 
that is a good thing 
that's come out of 
it.” 
 
“it's very distressing 
for the nurses when 
people can't get 
medicine that they 
think that they 
should get. Um, and 
you know, and I 
think that they're 
willing to try 
alternatives and do 
whatever. But I do 




They look at 
someone and say, this 
person’s in pain 
leading kind of 
questions 
I would color it 
cherry picking the 
answer 
hard stop from the 
physicians 
play them off each 
other a little bit 
advocate for their 
person 
a hard stop 
validate the use of 
that drug 
biggest advocates 
anticipate needs and 
advocate for their 
patients. 
nurses call and beg 
nursing care when it 
comes to treatment 
138 
 
they feel that they're 
the patient 










Limited Impact Within 
Hospice 
Codes refer to the 
perception that the 
specialty of hospice 
has had limited 




industry as a whole 
is really stepping up 
to say we're going to 
provide comfort, 
dignity, the end of, at 
the end of life, no 
matter what that 
takes.” 
 
“I don't feel…that 
the majority of 
people who are 
being victims of the 
opioid crisis are 
hospice patients” 
hospice world… the 
safest environment 
 
where do you kind of 
draw the line 
 
the definition of 
Palliative Care, look, 





ability to follow up 
on people 
picking them up 
sooner. 






These codes refer to 
the identification by 
the clinician of an 
organizational or 
system problem 




factors identified are 
leadership issues, 
lack of resources, 
and problems with 
other specialties.  
 
“a lot of these things 
are in that kind of 
lost to followup 
what's gonna happen 
when they leave here 
continue that 
whenever they leave 
here 
the way this practice 
is set up 
my boss 
I'm a consultant 
where are they going 
to go 
portrayals of risk 
so much fear 




lost to followup 
category where I just 
don't know what 
happens when they 
leave here.”  
 
“Can I find an 
oncologist, primary 






enough what my 
intent was to 
continue that 
whenever they leave 
here. Um, I think 
there are still big 
gaps across the 
country, but in 
particular I see it 
here where even 
with outpatient 
providers there, 
there's just a lack of, 
I guess follow up 
with agreeability to 





the DEA's going to 
come after them 
 
difficulty getting 
providers in the 
community to even 
prescribe 
 
it's hard to be the 
enforcer of regulation 
and policy 
 
they feel like they're 
overmedicating 
get somebody else to 
do it. 
you're going to be in 
the bullseye if you 
write opioids 
could hasten his 
demise 
Facilitating the death 
of the patien 
Determination of patient 
appropriateness/Referrals 
Codes refer to issues 
specific with the 
scope and definition 
of palliative care vs 
hospice 
 
“where do you kind 
of draw them line 
and sort of what 
don't know how to 
label patients 
palliative care is 
appropriate … 
everybody in the 
hospital 
shift the continuum 






patients are really in 




“I worry if that will 
shift the continuum 
where we do get an 
exception because 
our patients do have 
a different need. If 
we just label 
everybody that has 
chronic pain now has 
a palliative need, 
then I think that 
we're really 
potentially doing a 
disservice to patients 
that have serious 
illness.”  
no longer curative 
intent 





recalcitrant to have 
palliative care is on 
board 




well we'll just get 
somebody to come to 
your house 
Regulatory Influence: 
Protections vs Pressures 
Codes refer to the 
perception of the 
clinician that they 
are protected 









palliative care and 
they use the word 
palliative care. Um, 
so, um, I feel like I 
personally and 
professionally and 
protected because I 
professionally 
protected 
They're not looking 
at hospice doctors 
these people that are 
dying 
didn't have the 
umbrella that would 
protect him. 
specifically excluded 
doesn't apply to the 
STOP Act 
stop prescribing 
swung the pendulum 
a little too far 
regulatory body is 
going to sweep in 
the government 
would be after them 
fear of…the DEA 
141 
 




“the STOP Act. 
Sounds pretty scary, 
doesn't it? Like the 
STOP Act, you 
know, stop 
prescribing is the 
message I get from 
that, but I'm not 
going to stop 
prescribing.”  
pendulum has swung 
carve out that line 
numbers are being 
tracked and reported 
they're getting 
official letters 
 
 
 
